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ABSTRACT
Spinal cord injury affects more than 12,000 individuals in the US annually.
Currently, no FDA approved drug treatment is available for the acute care of these
individuals. Estrogen (E2), as a naturally occurring steroid hormone, is a potential
answer. As a highly pleiotropic agent, E2 is known to have anti-inflammatory, antiapoptotic, angiogenic, and neurotrophic properties, making it ideal for use in the
treatment of a highly complex, multi-faceted condition such as SCI.

Safety

concerns around the use of high doses of E2 have limited its application clinically.
To address these concerns, a nanoparticle delivery approach was used. Low
doses of E2 (25 - 2.5 µg) were formulated in nanoparticles and embedded into gel
patches that were placed directly on contused spinal cord tissue, allowing for focal
delivery. Plasma E2 levels revealed exposure profiles distinct from traditional dose
routes, potentially conferring increased efficacy. To further understand novel early,
intermediate, and chronic neuroprotective mechanisms that E2 exerts, a 6hr, 48hr,
and 28 day rat model of SCI was utilized. In the peracute (6hr) model, cytokine
and chemokine profiling was conducted in plasma, tissue, and CSF which allowed
for identification of biomarkers as well as novel targets of E2 regulation. Data
revealed a panel of factors regulated by E2, including IL-6, MCP-1, and GRO-KC,
etc. The intermediate model was used to test the hypothesis that E2 may drive
neuroprotection through modulation of glial cell response.

Data suggest E2

decreases various markers of glial cell reactivity and inflammation. Finally, a
chronic model was used to assess the potential of a single low dose nanoparticle
delivered E2 to drive improvements in locomotor function. The lowest single dose
at which functional improvements may be seen, was found to be 5.0 µg of E2.
These findings illustrate the ability of focally delivered nanoparticle formulated E2
to reduce plasma exposures to physiologically relevant levels while maintaining
efficacy in a functional model. Taken together, these findings may help advance
E2 into clinical evaluation at safer doses, thus providing a treatment options for
SCI individuals.
ix

CHAPTER ONE
SIGNIFICANCE AND REVIEW OF LITERATURE

SIGNIFICANCE
An estimated 150,000-200,000 worldwide cases of spinal cord injury (SCI)
are diagnosed annually, with some 2.5 million people living chronically with
paralysis secondary to SCI. The societal cost of medical and rehabilitative care
for these individuals is immense with loss of mobility, independence, and
productivity. The cost to the individual is immeasurable. This is a population in
dire need of effective and safe therapeutics.
Currently, no FDA-approved drug exists for the treatment of acute SCI.
Methylprednisolone, has been widely used, albeit off-label, in the care of acute
SCI with limited efficacy and remains a controversial therapeutic that has yet to
garner FDA approval (Hall 2003, Bracken 2012, Breslin and Agrawal 2012,
Lammertse 2013, Schroeder, Kwon et al. 2014).
In the last thirty years, the field of neurotrauma research has seen an
abundance of novel and promising pharmaco-therapeutic interventions. The use
of single-agent targeted therapeutics in an enormously complex condition that
includes numerous pathophysiologies, such as inflammation, oxidative stress,
ischemia, glial scarring, etc., has not proven efficacious. Thus, evaluation of
broadly acting drug candidates, including the steroid hormone estrogen, is justified.
Estrogen (E2) is a highly pleiotropic agent that has been reported to
activate transcription of some 137 E2 regulated genes (Lin, Strom et al. 2004),
and it is known to have anti-inflammatory , anti-oxidant, anti-apoptotic, and
1

neurotrophic properties (Sribnick, Ray et al. 2004, Cuzzocrea, Genovese et al.
2008, Kumar, Lata et al. 2010, Samantaray, Sribnick et al. 2010, Kipp, Berger et
al. 2012, Evsen, Ozler et al. 2013, Elkabes and Nicot 2014). E2 has exhibited a
neuroprotective effect in SCI models (Yune, Kim et al. 2004, Cuzzocrea,
Genovese et al. 2008, Ritz and Hausmann 2008, Kachadroka, Hall et al. 2010,
Sribnick, Samantaray et al. 2010, Samantaray, Smith et al. 2011, Lee, Choi et al.
2012, Siriphorn, Dunham et al. 2012, Mosquera, Colon et al. 2014).
Additionally, E2 has shown a neuroprotective effect in traumatic brain injury
models (Soustiel, Palzur et al. 2005, Gatson, Liu et al. 2012, Zlotnik, Leibowitz et
al. 2012, Asl, Khaksari et al. 2013, Day, Floyd et al. 2013, Zhang, Hu et al. 2013)
and stroke models (Merchenthaler, Dellovade et al. 2003, Lebesgue, Chevaleyre
et al. 2009, Zhang, Raz et al. 2009, Ardelt, Carpenter et al. 2012, Perez-Alvarez,
Maza Mdel et al. 2012), suggesting E2 warrants clinical evaluation in the setting
of neurotrauma. However, the translation of E2 from preclinical models into
clinical practice with the FDA-approved drug Premarin (a cocktail of equine
conjugated estrogens also containing lesser amounts of androgens and
progestogens) has significant safety concerns (LaCroix, Chlebowski et al. 2011).
Short term E2 treatment used for contraception has been reported to be
significantly associated with increased risk of venous thromboembolism, with the
greatest risk occurring in less than a year of treatment and at the highest dose of
E2 (Lidegaard, Edstrom et al. 2002).

These safety concerns with traditional

systemic dosing (either tablet or intravenous injection) of E2 pose a hurdle for
2

movement into SCI individuals. A more sophisticated form of drug delivery, such
as nanoparticles that allow for site directed delivery of a drug, may provide for a
significant advancement in the drug delivery field, thereby reducing safety
concerns of E2.
Nanoparticle drug delivery systems have been shown to improve the
therapeutic index of drugs (Zhang, Gu et al. 2008). By focally delivering E2 to the
injured spinal cord directly, maximal efficacy may be achieved while keeping
systemic levels of E2 in a physiological range. This technique may effectively
increase the therapeutic window of E2.
Thus, in conclusion, by pairing the steroid hormone E2 with a nanoparticle
drug delivery technique the potential exists for the development of an effective and
safe therapeutic for use in SCI individuals.
Hypothesis: Focal delivery of estrogen via nanoparticles will maximize
therapeutic potential through enhanced bioavailability with increased functional
recovery..
Specific Aim 1: Characterize E2 release from nanoparticles and assess antiinflammatory potential of E2 in a peracute (6hr) rat SCI model

Specific Aim 2: Evaluate E2 nanoparticle neuroprotective effects in acute (48hr)
rat SCI model
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Specific Aim 3: Assess functional recovery in chronic model (4 week) of rat SCI.

The exploration of these specific aims will add to the knowledge of E2 as a
neuroprotectant in SCI and the capacity of nanoparticles to focally deliver E2 to
the injured spinal cord by:
RESULT 1: E2 was shown to be released in a time dependent manner from
nanoparticles in both an in vitro and in vivo model. E2 treatment acted as a rapid
anti-inflammatory in a 6 hr spinal cord injury model by significantly decreasing
various cytokines and chemokines in plasma, spinal cord tissue, and cerebrospinal
fluid (CSF).
RESULT 2: Nanoparticle E2 exerted neuroprotective effects in a 48hr model of
SCI by decreasing apoptosis, glial reactivity, and inflammation, and by increasing
growth factor expression.
RESULT 3: Nanoparticle E2 resulted in significant improvement in various
parameters of gait in a 28 day chronic model. These findings were seen in tandem
with improved bladder function and enhanced spinal cord tissue preservation.
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LITERATURE REVIEW
Introduction
The first known documented case of SCI has been dated to 2500 years BCE.
During that era, SCI was considered “an ailment not to be treated” (Donovan
2007). Tremendous advances have been made in the field since this ancient
beginning; however, a panacea for spinal cord injury remains elusive. Extensive
bench research has lead to a better understanding of the pathophysiology of SCI,
thereby uncovering potential therapeutic targets.

Novel therapeutics showing

promise in preclinical models of SCI have been translated into clinical trials.
This review will provide a brief historical overview, followed by a summary of the
mechanisms and pharmacological therapeutics studied over the past decade.
Finally, a focused review of the E2 spinal cord injury literature will be provided as
a background for the work presented herein.
Historical Overview:
The concept that SCI was an “ailment not to be treated” reflects the longlasting belief that the catastrophic nature of the injury and lack of regenerative
capacity of the spinal cord made the injury medically futile to treat. Over the
course of the last 4,000+ years, treatment for SCI was centered on surgical
interventions to stabilize and decompress the spine (Donovan 2007). Only in the
second half of the 20th century did scientists begin using pharmacologic
interventions.
5

The first randomized clinical trial investigating a pharmaceutical agent in
SCI was initiated in 1979 when the National Acute Spinal Cord Injury Study I
(NASCIS) investigated the efficacy of the synthetic glucocorticoid steroid
methylprednisolone (a derivative of prednisone, FDA approved 1955) in SCI
(Bracken 1992). Glucocorticoid steroids are potent anti-inflammatory and
immunosuppressant drugs, and in the first known publication investigating
steroids in spinal cord injury, researchers found that treatment with a high dose
of glucocorticoid steroid (dexamethasone) significantly improved the functional
recovery in a dog model of SCI (Ducker and Hamit 1969). These preclinical
findings, along with findings from many additional studies, were translated into
this seminal clinical trial in 1979. NASCIS I was followed by two subsequent
studies, NASCIS II and NASCIS III, both investigating doses and timing of
methylprednisolone treatment after SCI (Bracken, Collins et al. 1984, Bracken,
Shepard et al. 1990, Bracken, Shepard et al. 1997). The reported findings of
these trials have led to wide off-label use of methylprednisolone in acute SCI.
However, these studies have fallen under intense scrutiny and have not resulted
in FDA approval of methylprednisolone treatment in acute SCI.
The largest randomized clinical trial ever conducted in SCI investigated
the efficacy of monosialotetrahexosylganglioside sodium (GM-1), proprietary
name Sygen.

GM-1 is a ganglioside (complex glycolipid predominant in plasma

membrane) that through unknown mechanisms can elicit neuroprotective effects
in SCI by promoting neural outgrowth, repair and regeneration (Geisler, Dorsey
6

et al. 1991). As with the NASCIS trials, the potential effectiveness of this
therapeutic is controversial. The GM-1 study failed to report statistically
significant efficacy in a clinical setting (Geisler, Coleman et al. 2001). Due to lack
of efficacy, the current guidelines published by the American Association of
Neurological Surgeons (2013), do not recommend treatment with either
corticosteroids or GM-1 ganglioside.
While progress certainly has been made through clinical trials over the last
30 years, the need for effective pharmacological intervention in acute SCI
remains. The drug that has been most extensively clinically evaluated,
methylprednisolone, functions primarily as an immunosuppressant and antiinflammatory in the setting of acute ACI. Since these early days of SCI research
and clinical testing, inflammation is now accepted as only one of many
pathophysiological mechanisms in SCI. Animal models have demonstrated that
SCI is marked by a primary injury, that results from the mechanical trauma,
followed by a more insidious phase referred to as secondary injury (Tator and
Fehlings 1991). The secondary injury cascade begins within seconds of the
primary injury and results in further tissue damage, disruption of blood vessels,
ischemia, cell death, inflammation, Wallerian degeneration and glial scarring.
Considerable progress has been made to unravel the complex molecular signals
that drive secondary injury. These mechanisms, along with their cognate
therapeutic approaches, will be discussed in the following three broad categories:
acute, intermediate, and chronic mechanisms of secondary injury.
7

Figure 1. Metabolic Brain Disease, Cox et al. 2014
I. Acute Mechanisms
Hypoxia & Ischemia: One of the first pathophysiological changes to occur
immediately following a traumatic SCI is disruption of blood flow with resultant
hypoxia to the injured tissue. The mechanical trauma results in disruption of cell
membrane, vasospasm, hemorrhage, and loss of microvasculature necessary to
supply spinal cord tissue with oxygen and other vital nutrients. The loss of both
oxygen and nutrients to the spinal cord immediately following injury triggers the
subsequent secondary injury with influx of Ca2+, calpain and caspase activation,
glutamate excitotoxicity, and inflammation. Hypoxia, therefore, contributes to the
expansion of the primary lesion (Tator and Fehlings 1991, Tator and Koyanagi
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1997). Pharmacological agents that have the capacity to restore oxygen and
nutrients to the damaged region of the spinal cord have been an area of research
interest. One such compound that has been studied is Oxycyte (a new
generation perfluorocarbon), an oxygen carrier that can be intravenously injected
to increase oxygen availability in damaged tissue. Oxycyte treatment in a rat
model of moderate-severe contusion spinal cord injury significantly increased
oxygen saturation and reduced apoptotic cell death with better tissue and myelin
preservation, respectively (Schroeder, Highsmith et al. 2008, Yacoub, Hajec et
al. 2013).

Additionally, Oxycyte treatment was shown to reduce spinal cord

lesion size in a swine model of decompression sickness (Mahon, Auker et al.
2013). Oxycyte may be suitable as an adjunctive therapy in the treatment of
SCI; Oxycyte treatment ideally should begin at the earliest possible time point
following an acute injury to lessen the detrimental cascade triggered by hypoxia.
The mechanical trauma from the initial injury will cause massive
disruption in both macro and micro vasculature that will disrupt blood flow to the
spinal cord and result in ischemia. Numerous studies have reported that
ischemia contributes to the subsequent neuronal degeneration and loss of motor
function in SCI (Anthes, Theriault et al. 1995, Tator and Koyanagi 1997, Muradov
and Hagg 2013). Ischemia, unlike SCI, can be studied as a single entity to
provide some enlightenment about the contribution it plays in the complex
network of mechanisms driving secondary injury. Researchers have attempted
to determine what role ischemia plays in SCI using a model of focal ischemia in
9

the spinal cord to investigate effects on axonal degeneration. Focal ischemia
alone has been reported to cause both loss of sensory axons and death of
oligodendrocytes (Muradov, Ewan et al. 2013); these findings suggest that
restoration of blood flow should be of utmost importance in the treatment of SCI.
In addition to triggering cell death, ischemic injury also activates microglia,
the resident macrophages of the CNS. Inhibition of microglial activation has
been shown to elicit neuroprotective effects (Cho, Cheong et al. 2011).
Activation of the toll-like receptor 4 on microglia may be a mechanism for
microglial activation in the setting of ischemic injury (rodent aortic occlusion
model) (Bell, Puskas et al. 2013). As research continues to further elucidate the
exact signaling mechanisms of ischemia that trigger the activation of microglia,
additional pharmacological targets may be identified. Activated microglia are
primary drivers of both innate and adaptive immune response through the
release of proinflammatory cytokines and chemokines (Schomberg and Olson
2012) and will be discussed in more detail in the inflammation section of this
review.
Excitotoxicity: Excitotoxicity is a pathological state in which high levels of the
excitatory neurotransmitter glutamate results in toxicity or death to neurons
(Doble 1999). Immediately following spinal cord injury, the levels of glutamate
can rise to excitotoxic threshold levels (Liu, Thangnipon et al. 1991). Glutamate
binds one of three receptors, N-Methyl D-Aspartate (NMDA), Alpha-amino-3hydroxy-5-methylisoxazoleproprionate (AMPA), or Kainate; the binding of
10

glutamate will modulate Ca2+ influx into the cell thereby regulating Ca2+
homeostasis and downstream signaling cascades (Mehta, Prabhakar et al.
2013). The potential critical role the NMDA receptor plays in mediating calcium
influx, has made it an attractive pharmacological target for many years now. The
NMDA receptor antagonist, MK-801, was reported to attenuate numerous
inflammatory markers in a mouse model of SCI (Esposito, Paterniti et al. 2011).
Although MK-801 cannot be used in SCI individuals due to toxicity, an
opportunity exists for the development of a safe NMDA receptor antagonist.
Riluzole (a sodium channel blocker / glutamate receptor modulator), approved for
the treatment of amyotrophic lateral sclerosis, has been shown in a preclinical
rodent study to act as a neuroprotectant through modulation of excitotoxicity
(Springer, Azbill et al. 1997, Schwartz and Fehlings 2001, Wu, Satkunendrarajah
et al. 2013) . A phase I safety trial of Riluzole in acute cervical spinal cord injury
individuals reported a rate of complication with drug use similar to that of
matched individuals, as well as an enhanced improvement in motor score with
drug- treated individuals compared to matched individuals (Grossman, Fehlings
et al. 2013). Follow-up placebo controlled trials evaluating Riluzole in SCI
individuals are anticipated.
Downstream effectors of excitotoxicity, such as the activation of
intracellular proteases, provide additional targets for therapeutic intervention.
Calpain, a Ca2+ activated cysteine protease, has emerged as a potential target in
SCI.

The role of calpain in spinal cord tissue degeneration has been discussed
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in the scientific literature for over 30 years (Banik, Powers et al. 1980, Banik,
Hogan et al. 1982). Mechanistically, the role of calpain in spinal cord tissue
degeneration has been further elucidated over the past 10 years. Studies have
shown that apoptosis following SCI requires de novo protein synthesis and can
be blocked with a pharmacological inhibitor of calpain (Ray, Matzelle et al. 2001,
Ray, Hogan et al. 2003). Rodent studies have shown an improvement in both
tissue and motor function recovery after treatment with various synthetic calpain
inhibitors (Arataki, Tomizawa et al. 2005, Sribnick, Matzelle et al. 2007, Akdemir,
Ucankale et al. 2008, Yu, Joshi et al. 2008). Calpain inhibition by the
endogenous inhibitor, calpastatin, has also been shown to be involved in
Wallerian degeneration in an optic nerve transection model (Ma, Ferguson et al.
2013). These findings suggest that both early and prolonged inhibiton of calpain
may provide protection against both apoptosis and Wallerian degeneration. Over
the years, a number of calpain inhibitors have been investigated (leupeptin,
calpeptin, E64D) (Ray, Wilford et al. 1999, Momeni and Kanje 2006, Tsubokawa,
Solaroglu et al. 2006); however, difficulties with drug safety and solubility have
precluded advancement of these compounds into the clinic. Currently,
researchers have an intense interest in the development of a targeted safe
therapeutic to inhibit pathological calpain activation.
Melatonin, a naturally occurring hormone, has also been reported to show
beneficial effects in SCI, potentially through mechanisms modulating calpain
activation (Samantaray, Sribnick et al. 2008). Numerous rodent models of SCI
12

have shown increased neuroprotection with melatonin treatment (Fujimoto,
Nakamura et al. 2000, Esposito, Genovese et al. 2009, Park, Lee et al. 2010,
Park, Lee et al. 2012, Schiaveto-de-Souza, da-Silva et al. 2013). Melatonin is a
pleiotropic agent, and thus may exert neuroprotective effects through its antioxidant, anti-nitrosative, and immunomodulatory mechanisms (Samantaray, Das
et al. 2009). The abundance of preclinical studies reporting neuroprotection with
melatonin treatment as well as melatonin’s high safety profile make melatonin a
potential candidate for clinical trial investigation as either a stand-alone agent or
as an adjunctive therapeutic in acute SCI treatment.
II. Intermediate Mechanisms
Inflammation: The acute mechanisms of hypoxia, ischemia, and excitotoxicity
give rise to an inflammatory response that contributes to the expansion of the
secondary injury. In rodent models, activation of resident astrocytes and
microglia can be seen as early as 2 hours following injury and persist up to 6
months (Gwak, Kang et al. 2012). Human studies have shown that the first
peripheral immune cell to enter the spinal cord lesion site is the neutrophil, which
arrives as early as 4 hours post injury; activated microglia were found at 1 day
post injury, and macrophages were seen by day 5 (Fleming, Norenberg et al.
2006). In animal models, blockade of neutrophils has been found to decrease
markers of inflammation following SCI (Chatzipanteli, Yanagawa et al. 2000,
Gris, Marsh et al. 2004). These findings suggest that, mechanistically,
neutrophils may contribute to the inflammation seen post SCI.
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Significant advances in the understanding of the complex role of
macrophages in SCI have revealed macrophages play dual roles as both proand anti-inflammatory mediators. Results of rodent studies indicate that altering
the ratio of M1/M2 macrophages in favor of the anti-inflammatory M2 may
promote regenerative growth (Kigerl, Gensel et al. 2009, Busch, Hamilton et al.
2011) The complexity of macrophage signaling and therapeutic potential are
beyond the scope of the current review; however, signaling is detailed in two
recent review articles (David and Kroner 2011, Ren and Young 2013). While
modulating the types of cells present in the setting of acute neurotrauma may
represent an avenue for therapeutic intervention, another important approach is
regulation of cell signaling.
Inflammation in the central nervous system is thought to be regulated by
the nuclear transcription factor, nuclear factor kappa β (NF-Kβ). Blockade of NFKβ, thereby, may be a therapeutic approach for decreasing inflammation. A
transgenic mouse model of SCI, where NF-Kβ is selectively inhibited in
astrocytes, has been reported to show decreased inflammation as well as
increased axonal sprouting (Brambilla, Bracchi-Ricard et al. 2005, Brambilla,
Hurtado et al. 2009). Regulation of inflammation via modulation of gene
transcription has also been tested with Thiazolidinediones (TZDs), synthetic
agonists of the ligand-activated transcription factor peroxisome proliferatoractivated receptor-gamma (PPARγ).

One such TZD, pioglitazone, has been

tested in a rat model of SCI as a potential neuroprotectant. The authors reported
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a significant decrease in inflammatory gene expression with enhanced motor
function recovery in a rat SCI model that were only seen when drug treatment
began within 2 hours of injury induction (Park, Yi et al. 2007). These findings
highlight the critical role early inflammation may play in SCI.
Apoptosis: Loss of cells in the spinal cord following injury may be attributable to
both apoptosis and necrosis. Necrosis, caused by mechanical tissue damage, is
considered irreversible. In contrast, apoptosis is regulated through cell signaling
and may be triggered by a variety of external or internal stimuli, thereby
becoming an attractive candidate for pharmacological modulation. Cellular
stressors triggering release of pro-apoptotic signaling molecules from the
mitochondria and activation of death receptors are the two broad independent
pathways through which apoptosis is triggered (Green 1998). The last 10 years
of research into mechanisms of apoptosis specific to SCI have yielded many
promising therapeutic targets. One potential modulator of apoptosis in SCI is cell
cycle activation. The cell cycle inhibitor, flavopiridol, was shown to reduce both
neuronal and oligodendrocyte apoptosis in a rat model of severe SCI (Byrnes,
Stoica et al. 2007). Another potential modulator is Phospholipase A2 (PLA2); a
lipolytic enzyme thought to contribute to neurodegeneration in secondary injury,
which has recently been implicated in the pathogenesis of SCI through its ability
to induce neuronal death when injected into normal spinal cord tissue (Liu, Zhang
et al. 2006). An animal study has shown that PLA2 is upregulated following
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injury in vivo and blockade of PLA2 in vitro protects against oligodendrocyte cell
death (Titsworth, Cheng et al. 2009).
An additional promising anti-apoptotic therapeutic is the antibiotic
Minocycline, which has been shown in numerous animal models to decrease
apoptosis (Stirling, Khodarahmi et al. 2004, Takeda, Kawaguchi et al. 2011,
Watanabe, Kawaguchi et al. 2012, Sonmez, Kabatas et al. 2013). Treatment
with Minocycline has also shown functional improvement in a number of
preclinical models (Wells, Hurlbert et al. 2003, Teng, Choi et al. 2004). Based on
these preclinical studies, Minocycline was evaluated for safety in a placebo
controlled phase II clinical trial in acute SCI individuals. The authors report that
the drug regimen was safe and well tolerated and suggested improved motor
function in individuals with cervical injuries (Casha, Zygun et al. 2012). The
positive results of the minocycline phase II clinical trial warrant further
investigation of drug efficacy in a phase III multi-center placebo controlled trial.
Hypothermia (both epidural and systemic) has been found to decrease
apoptosis in a rat model of SCI (Ok, Kim et al. 2012). Two clinical trials
investigating the safety and potential benefit of modest hypothermia in acute
cervical spinal cord injury reported promising results for both safety and potential
neuroprotection (Levi, Casella et al. 2010, Dididze, Green et al. 2013). As
hypothermia treatment is posited to potentially provide an early adjunctive
therapeutic in the treatment of SCI, additional clinical studies investigating
hypothermia are warranted.
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III. Chronic Mechanisms
Epigenetic Alterations: Over the last 10 years, the field of epigenetics has
expanded to include research into the mechanisms that may limit the central
nervous system’s ability to regenerate. More specifically, researchers have
speculated that the mature chromatin status of the cells comprising the spinal
cord may be blocking these cells from reactivating the developmental programs
necessary to successfully rebuild the damaged tissue (York, Petit et al. 2013).
DNA methylation, chromatin structure, and histone acetylation status are the
broad categories of epigenetic modifications that drive changes in gene
expression. Histones, the spool-like proteins that DNA winds around to achieve
the highly condensed state in chromatin, can be modified through acetylation.
The acetylation status of a histone will then drive gene silencing or transcription.
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, has been found to
reduce gliosis and increase production of both brain and glial-derived
neurotrophic factors in a rodent model of SCI (Abdanipour, Schluesener et al.
2012). Another study in rodent SCI has reported that treatment with VPA can
decrease gliosis and improve functional outcomes in open-field behavioral
assays (Lu, Wang et al. 2013). The field of epigenetic regulation in both spinal
cord injury and, more broadly, in neuroregeneration is arguably still in its infancy.
A tremendous promise exists in the approach of selectively regulating gene
expression to simultaneously decrease degenerative processes and increase
regenerative processes that will ultimately drive restoration of damaged nervous
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tissue. Hopefully, as this field matures an emergence of new therapeutics will
provide the tools necessary to achieve these goals.
Blockade of Myelin Inhibitors: Regeneration of axons following injury is
inhibited by a number of molecules, such as NoGo, myelin associated
glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgP) (Hunt,
Coffin et al. 2002). The existence of these inhibitors and their ability to block
regeneration have been known since the late 1980s (Schwab, Kapfhammer et al.
1993). Early publications in the field of axon regeneration have shown that
blockade of NoGo with the IN-1 antibody promoted regrowth after injury in animal
models (Schnell and Schwab 1990, Brosamle, Huber et al. 2000). The exact
contribution of these molecules to successful axon regeneration in vivo, however,
is not yet clearly defined, as a recent publication investigating the role of these
three inhibitors demonstrates. The authors of this publication exhibit this by
using mutant transgenic mouse models that block of all three myelin inhibitors
(NoGo, MAG and OMgP) and when compared to blockade of any single inhibitor
it failed to show additive effects (Lee, Geoffroy et al. 2010). These authors state
that while “MAG, NoGo, and OMgp may modulate axon sprouting, they do not
play a central role in CNS axon regeneration failure” (Lee, Geoffroy et al. 2010).
Regardless of the exact role each of these inhibitors may play in spinal cord
regeneration, the wealth of positive preclinical findings with pharmacological
blockade has resulted in two agents moving into clinical evaluation. The two
agents, ATI-355 (humanized anti- Nogo antibody, Novartis) and Cethrin
18

(recombinant protein RHO GTPase antagonist, BioAxone BioSciences) are being
clinically evaluated for their potential to modulate axon regeneration in SCI.
Results from the ATI-355 trials have not yet been released, although the trial was
registered as complete in November, 2013. Results from the phase I/IIa clinical
trial reported Cethrin to be safe and tolerable in acute SCI individuals, and
suggested that Cethrin enhanced motor function recovery (Fehlings, Theodore et
al. 2011). Cethrin works by inhibiting the RHO pathway, the final common
signaling pathway of the myelin inhibitors. To date, Cethrin is the only drug to
attain orphan drug status from the FDA (2005) in the treatment of acute cervical
and thoracic spinal injuries. The next step in the development path of Cethrin will
be a placebo-controlled efficacy trial.
Myelin Regeneration & Scar Remodeling: Progesterone, a naturally occurring
steroid hormone, has emerged as a potential therapeutic in SCI through findings
that suggest it may serve as both a neuroprotectant and pro-myelinating agent.
Results of a study conducted in a rat SCI model indicated that treatment with
progesterone resulted in sparing of white matter tissue with concomitant
improvement in motor function (Thomas, Nockels et al. 1999). A mechanistic
study examining the effects of progesterone in a rat model of SCI reported that
progesterone treatment restored myelin levels and increased the density of
oligodendrocyte progenitor cells, which are potentially responsible for
remyelination (De Nicola, Gonzalez et al. 2006). An additional study reported
that progesterone may work by suppressing gliosis at the early stage of SCI
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while promoting oligodendrocyte differentiation and remyelination at the later
stages (Labombarda, Gonzalez et al. 2011).
Glial scarring and wound cavitation are thought to be major inhibitors of
spinal cord regeneration in the chronic phase. One of the major proteins
involved in the glial scar is chondroitin sulfate proteoglycan, which is produced by
activated glia, and serves to block regrowth of axons across the injury (Cregg,
DePaul et al. 2014). The protein tyrosine phosphatase σ has been identified as a
key receptor in the process of growth cone dystrophy, and antagonism of this
receptor is reported to lead to increased regeneration in injured rats (Lang, Cregg
et al. 2015). Another recent approach to enhance regeneration has been to use
microtubule stabilizing drugs. Epothilone B, a FDA approved microtubule
stabilizing drug that is BBB penetrant, was found to activate microtubule
polymerization and growth through the inhibitory environment of the glial scar,
resulting in enhanced motor function recovery (Ruschel, Hellal et al. 2015).
Recently, a pan Tgfβ 1/2 antagonist, Decorin, was shown to decrease wound
cavitation and scar tissue mass through suppression of inflammatory fibrosis
(Ahmed, Bansal et al. 2013). The authors of this study also reported that Decorin
treatment has potential for dissolution of mature scars through induction of matrix
metalloproteinases with subsequent axonal regeneration.

The concept that

existing scar tissue may be remodeled to drive regeneration is an exciting one,
as it would potentially offer a treatment option to individuals chronically living with
paralysis due to SCI.
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ESTROGEN
Background
Estrogen (E2) is a widely studied hormone that has over 225,000
PubMed citations. The bulk of these citations are focused on E2 in reproduction,
development, and cancer, however. It wasn’t until 1988, that a paper was
published suggesting E2 may play a neurotrophic role in the injured CNS (Jones
1988). E2 was first reported to attenuate neuronal injury experimentally in an in
vitro model of hemorrhage, trauma, and ischemia, wherein E2 decreased
neuronal loss (Regan and Guo 1997). E2 was then used in a peripheral nerve
injury model and found to enhance sciatic nerve regeneration following crush
injury (Islamov, Hendricks et al. 2002). The first in vivo report of E2 in spinal cord
injury was made in 2003, where the authors report that a single 4mg/kg
intravenous dose of E2 reduced infiltration of macrophages/microglia into the
injured spinal cord (Sribnick, Wingrave et al. 2003). Since then more than 80
papers have been published in the field investigating the effects of E2
administration in various models of spinal cord injury. A recent review article has
summarized all the in vivo E2 experiments conducted up to 2014 and their
primary findings (Elkabes and Nicot 2014).
Mechanisms of Neuroprotection
E2 binds to its cognate steroid hormone receptors ERα and
ERβ, translocates to the nucleus, binds to estrogen response elements alongside
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additional co-factors, and is responsible for either directly or indirectly activating
transcription of some 137 estrogen regulated genes (Lin, Strom et al. 2004).
This has been the classical understanding of the steroid hormone receptor
signaling pathway; however research has shown that E2 also exerts its effects
through an additional receptor as well as non-receptor mediated mechanisms.
E2 binds the G-protein coupled receptor 30 (GPR30), and it has been
shown that this signaling pathway can mediate apoptosis in neurons of the
injured spinal cord (Liu, Han et al. 2011, Chen, Hu et al. 2015). Activation of
ERα, ERβ, and GPR30 result in activation of the extracellular signal-regulated
kinase 1 (ERK1) and the phosphoinositide 3-kinase (PI3K) signaling pathways,
as recently reviewed and illustrated in the figure below (Arevalo, Azcoitia et al.
2015).

22

Oestradiol enhances the expression of anti-apoptotic genes and
neuroprotective growth factors and represses the expression of pro-apoptotic
genes and pro-inflammatory molecules in the brain. This action of the
hormone is mediated by two redundant mechanisms: the binding to the
intracellular oestrogen receptors (ERs) ERα and ERβ and subsequent
regulation of ER-mediated transcription, and the binding to membrane
receptors (ERα, ERβ and G protein-coupled ER (GPER)) and subsequent
regulation of kinase-activated transcription factors by the activation of
phosphoinositide 3-kinase (PI3K)–AKT, extracellular signal-regulated kinase
1 (ERK1)–ERK2, and Janus kinase (JAK)–signal transducer and activator of
transcription 3 (STAT3) signalling.
Figure 2. E2 signaling cascades (courtesy of Arevalo et al. The
Neuroprotective actions of oestradiol and oestrogen receptors. Nature Reviews
Neuroscience, 2015)
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The signaling cascades diagrammed (Figure 2) are activated in numerous
cell types within the CNS. All three major cell types: neurons, astrocytes, and
oligodendrocytes have been shown to express the enzymes necessary for
production of E2 (Garcia-Ovejero, Azcoitia et al. 2005). E2 receptors ERα,
ERβ, and GPR30, are also widely expressed (Spence, Wisdom et al. 2013).
Finally, E2 itself may function as an antioxidant directly through its properties as
a hydrophobic phenolic type molecule (Moosmann and Behl 1999). Given the
potential for E2 to elicit various cell signaling pathways in a variety of cell types,
there is enormous potential for E2 to drive neuroprotection through varied
mechanisms in an injury setting.
E2, more specifically, may serve as a neuroprotectant in part due to its
action as an anti-apoptotic along with its actions as an anti-inflammatory,
antioxidant, and as a promoter of angiogenesis. Numerous studies conducted in
a rat SCI model have shown a reduction in apoptosis and/or improved locomotor
function recovery with E2 (or Premarin) treatment (Chen, Yeh et al. 2010,
Sribnick, Samantaray et al. 2010, Samantaray, Smith et al. 2011, Siriphorn,
Dunham et al. 2012). A recent study reported that E2 treatment protected
against oligodendrocyte cell death mediated via the RhoA-JNK3 pathway in a rat
model of SCI (Lee, Choi et al. 2012). Preservation of oligodendrocytes is key to
preventing the Wallerian degeneration seen in the secondary injury phase of SCI.
E2 may also be exerting neuroprotective effects by modulating excitotoxicity.
More specifically, E2 was reported to upregulate expression of the glutamate
24

transporter 1 (glial specific glutamate transporter) along with the Kir4.1 channel
(inwardly rectifying potassium channel) expression in a rat SCI model (Olsen,
Campbell et al. 2010). Since E2 binds to its cognate receptor and, thus, can
regulate expression of 137 genes, E2 may be simultaneously driving
neuroprotection through numerous mechanisms (Lin, Strom et al. 2004). Given
the highly pleiotropic nature of E2 and the robust preclinical findings, E2 is a
promising candidate for continued development as a therapeutic in SCI.
Clinical Translation & Nanoparticle Delivery
Long term E2 treatment (5 years) in post-menopausal women is known to
carry adverse risks of cardiovascular disease, cancer, stroke, and pulmonary
embolism; as studies conducted by the Women’s Health Initiative (WHI) have
reported (Rossouw, Anderson et al. 2002). Shorter term E2 treatment used for
contraception is reported to be significantly associated with increased risk of
venous thromboembolism- with the greatest risk occurring in less than a year of
treatment and at the highest dose of E2 (Lidegaard, Edstrom et al. 2002).
Spinal cord injury individuals are at a heightened risk for development of
thromboembolic complications (Waring and Karunas 1991). Given this increased
risk, special consideration must be made to not compound the risk with
pharmacological treatments. Thus, while preclinical data are very promising to
suggest E2 as an effective therapeutic, these safety concerns with traditional
dosing of E2 pose a hurdle for movement into SCI individuals. More
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sophisticated forms of drug delivery, such as nanoparticles, may provide a better
option.
Nanoparticles, synthetic polymers capable of carrying and targeting
delivery of drugs, have shown great promise for rational, focused drug
administration. The first nanoparticle formulated drug to garner FDA approval for
the treatment of cancer was Doxil, in 1995 (Gabizon and Martin 1997). Doxil is
a pegylated (poly-ethylene glycol coated) liposomal nanoparticle carrying the
chemotherapeutic doxorubicin. The liposomal formulation of the drug allowed for
preferential accumulation into the skin making it uniquely suited for the treatment
of Kaposi’s sarcoma. This example highlights the advantage that nanoparticle
formulated drugs can offer - targeted drug delivery. The vast majority of research
into nanoparticle drug delivery has been conducted in oncology, and has yielded
at least 11 FDA approved nanotherapeutics with at least 9 more being evaluated
in phase III clinical trials (Marchal, Hor et al. 2015). While the field of
nanotherapeutics first gained success in oncology these advances can now be
applied to neurotrauma research.
The use of nanoparticles as a drug delivery system for CNS disorders is a
burgeoning field that will allow for focal drug delivery. By site-directed
administration of E2 in a nanoparticle formulation, sustained high localized tissue
concentrations may be achieved while keeping the overall systemic exposure
relatively low, thereby reducing risk of high dose E2 exposure related toxicities to
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the patient. Indeed, nanoparticle drug delivery systems have been shown to
improve the therapeutic index of drugs (Zhang, Gu et al. 2008).
Nanoparticles have the potential to increase the therapeutic index of
drugs, however, the question of how to focally deliver E2 loaded nanoparticles to
the spinal cord remains. A recent exploratory delivery technique whereby
embedded agarose gel plugs with MP loaded nanoparticles that were placed
directly onto lesioned tissue in a rat SCI model illustrated the feasibility of our
approach (Chvatal, Kim et al. 2008). Given acute spinal cord trauma individuals
are likely to undergo spine stabilization surgery, delivery of the nanoparticles
directly via a surgically implanted gel patch also remains a translational
approach.

MP has been shown to be released from the agarose gel

preparation and to penetrate the spinal cord exerting its anti-inflammatory effects.
High dose methylprednisolone given via traditional oral or intravenous routes
have been used for more than 30 years now for the treatment of acute SCI, albeit
off label, and remains quite controversial as it acts as an immunosuppressant
and lacks robust efficacy. Therefore, further development of nanoparticle
methylprednisolone may not be warranted. However, given the robust and
promising preclinical data with E2 development of a nanoparticle delivery
approach is suggested. By focally delivering E2 to the injured spinal cord
directly, maximal efficacy may be achieved while keeping systemic levels of E2 in
a physiological range. This technique may effectively increase the therapeutic
window of E2.
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CHAPTER TWO

ESTROGEN RELEASE FROM NANOPARTICLES AND E2 AS
AN ANTI-INFLAMMATORY IN A PER-ACUTE RAT MODEL OF SCI

Introduction
Nanotherapeutics in SCI is a relatively new area of research. Work in this
area began with numerous studies investigating the capacity of polymers such as
PEG and other nanotechnologies to be used as wound sealants in the damaged
spinal cord. The focus herein will be on nanoparticle drug delivery; other reviews
may be referenced for these earlier studies (Cho and Borgens 2012).
Nananoparticle drug delivery can be divided into two distinct approaches,
systemic delivery and site directed. Systemic delivery is administration of a
nanotherapeutic via intravenous (IV), oral gavage, or intraperitoneal (IP) dosing
techniques such that the nanotherapeutic will be distributed via the bloodstream
throughout the body. Site directed delivery approaches will allow for therapeutics
to be placed directly onto injured/diseased tissue. This approach may allow for
increased tissue concentrations of drug, thus enhancing efficacy while sparing
toxicities associated with high systemic dosing regimens.
Recently, a group has published two papers describing
methylprednisolone encapsulated into PLGA nanoparticles, embedded into
agarose gels, and then placed directly onto lesioned spinal cords (Chvatal, Kim
et al. 2008, Kim, Caldwell et al. 2009). Further, this group has evaluated the
difference between directly injecting methylprednisolone vs. nanoparticle gel
delivery for efficacy and reported that the nanoparticle delivered
methylprednisolone had better functional improvement. Another group has
reported a similar finding using glial derived neurotrophic factor (GDNF)
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encapsulated into PLGA nanoparticles. Here the authors used either an
intraspinal injection or a direct injection into lesion tissue and reported that only
the site-directed injection of GDNF nanoparticles resulted in functional
improvement (Wang, Wu et al. 2008).

Prostaglandin-E-1, Neurotrophin-3, and

flavopirodol loaded nanoparticles have also been reported to be efficacious in
spinal cord injury (Takenaga, Ishihara et al. 2010, Ren, Han et al. 2014, Elliott
Donaghue, Tator et al. 2015).
Given the success of these preliminary studies relied on site-directed
delivery of drug loaded nanoparticles we aim to apply these advances into an
investigation of E2 loaded nanoparticles in spinal cord injury. To begin this work
E2 release from the nanoparticle must be characterized in an in vitro system and
subsequently in a peracute (6hr) in vivo rat model of SCI. With these preliminary
data, illustrating that the nanoparticles can deliver E2 to the spinal cord, more
long term studies may be warranted.
Additionally, while much is known about the neuroprotective effects of E2
in sub-acute and chronic conditions (days to weeks), less is known about its
potential to mediate inflammation rapidly in a per-acute setting of SCI (6hrs). To
further elucidate the potential for E2 to rapidly modulate inflammation, the
cytokines IL-6 and GRO-KC (human IL-8), and the chemokine MCP-1 (candidate
biomarkers identified in a human a study (Kwon, Stammers et al. 2010)) were
investigated in plasma, cerebrospinal fluid (CSF), and spinal cord tissue of an
acute rat model of SCI. The calcium binding protein S100β, the most frequently
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cited biomarker studied in SCI (Yokobori, Zhang et al. 2013) was also
investigated in spinal cord tissue. As the potential exists for E2 to modulate
numerous targets, outside of those previously identified as biomarkers, a
complete cytokine/chemokine array will be used to fully characterize how E2 may
function as a rapid anti-inflammatory in SCI.

Sampling the plasma, CSF, and

tissue simultaneously will further understanding of the dynamics of using
plasma/CSF biomarkers to reflect the status of the injured nervous tissue. In
utilizing nanoparticles, we hypothesize that E2 concentration will be greater in
tissue than plasma and aim to keep systemic exposure at physiological levels.
Additionally, by using a multiplex cytokine/chemokine array approach in plasma,
tissue, and CSF, we hypothesize identification of novel cytokines/chemokines
that are targets of E2 modulation. Collectively, the data presented herein may
provide additional support for the clinical translation of this novel drug therapeutic
into the acute neurotrauma setting.

31

Materials and Methods
Nanoparticles and Gel Plug Delivery System
Nanoparticles: Nanoparticles were formulated at Clemson University
(Bioengineering Department) using the nanoprecipitation method previously
described (Maximov, Reukov et al. 2010, Satishkumar and Vertegel 2011).
Briefly, 50:50 PLGA (poly-lactic-co-glycolic acid) was mixed with PEG-PLA
copolymer, and 17-β estradiol (E2) (Sigma E2758) in a 10:2.5:1 (wt.) ratio. The
vehicle control batch was loaded with 0.9% saline. This was dissolved in acetone
to obtain a 5 mg/mL polymer solution. This solution was added drop-wise to 20
mL of de-ionized water in an ultrasonic water bath and sonicated for 30 minutes.
The formed particles were then separated by centrifugation (7500 rcf) for 2
hours, washed three times with de-ionized water, and lyophilized overnight. Each
batch was evaluated for particle size (dynamic light scattering), load efficiency,
and zeta potential to ensure consistency among batches. Nanoparticles were
stored in sucrose at -20°C.
Gel Plug Delivery System: Gel plugs (0.6% SeaPlaque agarose in PBS) were
made by dissolving lyophilized E2 loaded PLGA nanoparticles at either 25 µg or
2.5 µg dose (or saline loaded vehicle control) in 50 μL sterile filtered PBS. The
gel (final volume 50uL) was set in PCR amplification tubes overnight to harden.
Prior to insertion into animals, gels were sterilized under tissue culture UV lamp
for 15 minutes.
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Rat Model
All animal experiments were conducted in accordance with guidelines of the
Institutional Animal Care and Use Committee, and performed under the protocol
ARC #2079. Adult male Sprague-Dawley (SD) rats weighing 200-250 gm were
used. Five groups, each with n=6 animals per group were included in this study
as follows: (1). Naïve, (2). Sham, (3). Injury + nanoparticle vehicle control (Inj +
Veh), (4). Injury + 25 µg E2, and (5). Injury + 2.5 µg E2. The naïve group was
used to establish a baseline for cytokine/chemokine expression. Inclusion of this
group was intended to aid in identifying analytes that are changed due to
laminectomy procedure. Comparison of sham vs. injury + Veh group will identify
markers changed due to SCI. To generate the SCI model, animals were
anesthetized with ketamine (100 mg/kg) and xylazine (5 mg/kg), and a
laminectomy was performed at thoracic vertebrae 9 & 10 (T9 & 10), the dura
mater was left intact. The spine was immobilized with a spinal stereotactic
device, and a moderate to severe SCI was induced by the weight-drop model
(Perot, Lee et al. 1987). A weight of 5 gm was dropped from a height of 8 cm
onto an impounder (0.3 cm in diameter) placed on the dural surface of the spinal
cord. Sham animals undergo only a T9 &10 laminectomy.

Immediately

following the injury induction, the sterile gel plug was placed directly on the dural
surface of the contused spinal cord, filling the space voided by the laminectomy
(Figure 3).
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Figure 3. E2 Nanoparticle Gel Plug Approach A. PEG decorated nanoparticle
loaded with Estrogen B. Estrogen loaded nanoparticles embedded in gel plug C.
Spinal cord contusion injury D. Placement of gel plug onto lesion
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The incision was sutured, and animals were monitored for 6 hours until
euthanasia. At the 6hr time point, animals were deeply anesthesized with
isoflurane, and whole blood was drawn via cardiac puncture into EDTA-coated
tubes for E2 concentration analysis and cytokine profiling. CSF was collected via
cisterna magna puncture and flash frozen in liquid nitrogen for cytokine profiling
via ELISA. For CSF analysis, only clear samples completely devoid of blood
contamination were analyzed. Animals were decapitated, and a necropsy was
performed to collect a 1 cm section of spinal cord taken centered on the lesion
site (0.5 cm caudal to lesion epicenter taken with 0.5 cm rostral to epicenter). At
necropsy all gel plugs were observed to have remained in place, and the gel plug
was removed and discarded prior to tissue collection. Tissue was flash frozen in
liquid nitrogen and stored at -80°C until processing. Naïve animals were
euthanized in identical fashion, and samples were taken at same time of day as
in the experimental animals to control for potential circadian effects on
cytokine/chemokine levels.

Estrogen Concentration In Vitro & In Vivo
In Vitro: To evaluate the potential for E2 to be released from the nanoparticle

embedded agarose gel patch an in vitro release experiment was conducted. Gel

patches placed in complete cell culture media (RPMI 1640 + 10% FBS) maintained
in cell culture incubator for 32 days. E2 concentration was measured via

commercially available ELISA kit (Calbiotech ES180S).
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In Vivo: Plasma
Whole blood drawn via cardiac puncture was collected into EDTA containing
tubes (final concentration EDTA 1.5 mg/mL) and placed immediately on ice.
Whole blood samples were spun at 10,000 RPM in a Sorvall Legend Micro21
bench top centrifuge, and plasma was collected and stored at -80°C. 17-β
estradiol (E2) concentration was determined using a commercially available
ELISA kit (Calbiotech Estradiol ELISA ES180S). Undiluted samples were
processed following directions provided by the manufacturer.
In Vivo: Spinal Cord
Spinal cord tissue homogenate (aliquot of identical sample as used for cytokine
profiling) was diluted either 1:100 for the 25 μg E2 dose or 1:10 for the 2.5 µg E2
in 6% BSA block, and samples were run on same ELISA kit as plasma analysis.
Using protein concentration data gathered from Bradford assay, tissue sample
E2 concentration was then converted from pg/mL to pg/µg total protein to
account for differences in protein concentrations between samples.
Cytokine Profiling
Tissue: Spinal cord tissue samples were homogenized in 400µL of ice cold PBS
with a protease inhibitor cocktail (Sigma P1860, final dilution 1:200). Samples
were homogenized with a Polytron hand held tissue homogenizer set at
maximum speed for 30 seconds on ice. Samples were then sonicated briefly and
spun at 10,000 g for 20 min at 4°C. Supernatants were analyzed via Bradford
assay for protein concentration, and samples were normalized to a final protein
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concentration of 8 µg/mL with homogenizing buffer. Normalized samples were
stored at -80°C then shipped on dry ice to Eve Technologies
(www.evetechnologies.com) and run undiluted on the cytokine/chemokine 27plex discovery assay that included: Eotaxin, EGF, Fractalkine, IL-1α, IL-1 β, IL-2,
IL-4, IL-5, IL-6, IL-10, IL-12(p70), IL-13, IL-17A, IL-18, IP-10, GRO/KC, IFN-γ,
TNF-α, G-CSF, GM-CSF, MCP-1, Leptin, LIX, MIP-1α, MIP-2, RANTES, VEGF.
Plasma:
Plasma samples collected at necropsy were stored at -80°C then shipped on dry
ice to Eve Technologies. Samples were run undiluted on the rat
cytokine/chemokine 27-plex discovery assay.
Cerebrospinal Fluid: CSF was taken at necropsy, flash frozen in liquid nitrogen,
stored at -80°C, then shipped on dry ice to Eve Technologies. Samples were run
undiluted on the rat cytokine/chemokine 27-plex discovery assay. Three groups
(sham, Injury + 25 µg, Injury + 2.5 µg) contained only n=5 samples due to
omission of a sample with blood contamination.
Western Blot S100β
An aliquot of the spinal cord tissue homogenate that was used for cytokine profiling
was used for Western blotting, n=6 samples representative of the 6 animals per
group (n=24 total samples included in analysis). Using the data from the Bradford
assay for protein estimation samples will be diluted to 1.0 µg/µL concentration with
sample buffer [62.5 mM Tris–HCl, pH 6.8, 2% sodium dodecyl sulfate, 5 mM β37

mercaptoethanol, 10% glycerol] and boiled for denaturation. 12.5 µL (12.5 µg total
protein) of each sample will be loaded onto 4-20% precast gels (Bio-Rad
Laboratories, CA, USA) and resolved at 100 V for 1 and 1/2 hrs. Immunoblotting
was performed as described in a previous lab publication (Samantaray, Patel et al.
2013). The resolved gel was transferred to Immobilon™-polyvinylidene fluoride
microporous membranes (Millipore, MA, USA). The membranes were blocked for
1 hr with non-fat dry milk powder in wash buffer (0.1 % Tween-20 in 20 mM Tris–
HCl, pH 7.6) and immunoblotting was performed with primary antibody Anti-S100β
(Abcam rabbit monoclonal #ab52642) at 1:1000 overnight at 4°C and Anti-β-Actin
(Sigma mouse monoclonal #A2228) at 1:10,000 room temperature for 1hr. The
membranes were then incubated with horseradish peroxidase tagged secondary
antibodies (dilution 1:2000) tagged with (primary goat anti-mouse or primary goat
anti-rabbit antibodies) at room temperature. Chemiluminescent reagents (ECL
Prime, GE Healthcare) were used to detect the immunoreactive bands on the
membranes, and the images of protein bands were captured via Alpha Innotech
FluorChem FC2 Imager. The immunoreactive bands were quantified using NIH’s
Image J software. Given multiple gels were used to accommodate all of the
samples the data was analyzed as a percent of control. Sham animals were
defined to be 100% and the relative band intensity of the remaining animals was
normalized to the average of the sham group per gel.
Statistical Analysis: To test our hypothesis that E2 may significantly decrease
IL-6, MCP-1, and GRO-KC a one-way ANOVA test was performed using
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GraphPad Prism 5.0 with a Tukey’s multiple comparison post-test to determine
any differences between sham, Inj + Veh, Inj + 25 µg E2, and Inj + 2.5 µg E2
treated groups. Each test was conducted for each marker in the plasma, tissue,
and CSF compartments such that 9 one-way ANOVA’s were run. Significance
was defined as p<0.05. Additionally, as a screening tool to assess the
remaining markers the non-parametric Wilcoxon rank sum test was used to
detect differences among naïve, sham, Inj + Veh, and Inj + E2 treated groups.
SAS 9.3 software was used to perform the analysis. Each matrix was treated as
a separate group, and all of the analytes reported were included in the analysis,
such that for plasma, 75 comparisons were made; in CSF, 64 comparisons were
made; and in tissue, 75 comparisons were made. Significant differences were
defined as p<0.05. A false discovery rate (fdr) correction was made to account
for the multiple comparisons made within each statistical test. Both the
uncorrected exact p value and the fdr corrected exact p values are shown for
significant p values Inj + Veh vs. Inj + 25 µg / Inj + 2.5 µg in tabular form (tables
1-3).
Results
In Vitro E2 Release from Nanoparticle Gel Plug:
E2 levels continued to rise for 6 days (144 hours), and then showed a plateau in
concentration until day 32 (Figure 4). This data illustrates that E2 is released
from nanoparticles embedded in gel patches into cell culture media and provides
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the rationale for in vivo evaluation. Additionally, there were no overt signs of
bacterial or fungal growth in the media (devoid of antibiotics/antimycotics after 32
days of incubation with the E2 nanoparticle gel plug. Given this observation the
UV light sterilization technique was deemed acceptable for animal usage.
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Figure 4. Estrogen In Vitro Release Profile
Concentration of E2 released into culture medium from agarose gel patches embedded with 25 μg E2 nanoparticles. E2 concentration assayed on ELISA format.
Media serially sampled from 0, 2, 4, 6, 12, 24, 48hrs, and then every other day to
day 14 and a final sample taken on day 32.
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E2 Plasma Concentration: The E2 plasma concentration (mean ±SEM) of
animals in the sham group (14.6 pg/mL ±0.7) was comparable to the Injury +
Vehicle group (15.8 pg/mL ±0.9) (Figure.5). These values were within the range
of reported serum concentrations in female rats (during estrous/trough E2 levels)
using a radioimmunoassay technique (Strom, Theodorsson et al. 2008). E2
concentration in plasma at 6hrs post agarose gel plug placement was nearly tenfold higher in the 25 μg dose group (725.2 pg/mL ±175.2) vs. the 2.5 µg dose
group (81.6 pg/mL ±18.6) (Figure 5). Notably, the E2 concentration in the 2.5 µg
dose group was lower than reported E2 concentrations in female rats during
proestrous, or peak E2, at 300 pg/mL (Saddick 2014). This suggests that the
concerns of supraphysiological E2 dosing, as seen in humans taking high dose
contraception, may be avoidable using a focal nanoparticle delivery approach
that may allow for physiologically relevant plasma E2 levels .

42

Figure 5. Plasma E2 Concentration 6 hrs Post Injury E2 plasma
concentration was nearly ten-fold higher in the 25 μg dose group (725.2 pg/mL
±175.2) vs. the 2.5 µg dose group (81.6 pg/mL ±18.6), n=6 per group.
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E2 Tissue Concentration: The E2 tissue concentration (mean ±SEM) of animals
in the sham group (1.6 pg/µg ± 0.08) was comparable to the Injury + Vehicle
group (0.9 pg/µg ± 0.07) (Figure 6). E2 concentration in spinal cord tissue was
also nearly ten-fold higher in the 25 µg dose group (1564 pg/µg ± 366) vs. the 2.5
µg dose group (163 pg/µg ± 47) (Figure 6). This suggests that given the doses
chosen in this study, at this single time point, the nanoparticle E2 release is dose
linear. Additionally, the concentration of E2 (at both doses) is double in the tissue
as compared with plasma (Figure 7). This data provides evidence to support our
hypothesis that focal nanoparticle delivery of E2 may allow for increased tissue
concentrations over plasma.
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Figure 6. Spinal Cord Tissue E2 Concentration 6 hrs Post Injury E2
concentration in spinal cord tissue was nearly ten-fold higher in the 25 µg dose
group (1564 pg/µg ± 366) vs. the 2.5 µg dose group (163 pg/µg ± 47), n=6 per
group.
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Figure 7. Plasma and Tissue E2 concentrations 6 hrs Post Injury Tissue
concentrations were double that of plasma for both 25 µg (1564 pg/µg tissue vs.
725 pg/mL plasma) and 2.5 µg ( 163 pg/µg tissue vs. 82 pg/mL) E2 doses. N=6
per group
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CSF Cytokine/Chemokine Profiling: 18 of the 27 cytokines/chemokines profiled
were assayed at measurable levels. G-CSF, Eotaxin, GM-CSF, IL-5, LIX, TNFalpha, MIP-2, RANTES, and MIP-1A were found to be below the levels of
quantification (BLQ), and thus not reported. Both IL-6 and GRO-KC were
increased with SCI, and decreased with E2 treatment, however, did not reach
significance (Figure 8). MCP-1, however was found to be significantly increased
with SCI and significantly decreased at both doses of E2 (Figure 8). Using a
screening approach to evaluate the remaining markers IL-10, IL-2, IFN-γ, IL17a, and TNF-α were found to be increased with injury and decreased with E2
treatment (Table 1). Showing no change with either injury or E2 treatment were
IL-4, IL-13, and IL-18 (Table 1). IL-1β, IL-12p70 and leptin showed increased
levels with E2 treatment (Table 1). The growth factors EGF and VEGF had
slightly decreased levels in the 2.5 μg E2 dose group, and the remaining
chemokines (IP-10, Fractalkine, LIX, and RANTES) exhibited no change with
either injury or E2 treatment (Table 1). The factors that showed the greatest
change between sham and injury, recapitulating findings in a human CSF
biomarker study (Kwon, Stammers et al. 2010), were IL-6, MCP-1, and GRO-KC.
In summary, data suggest that E2 treatment at either the 25 or 2.5 μg dose may
modulate the following cytokines/chemokines in the CSF: IL-1α, IL-6, IL-10, IL-2,
IL-10, IFN-γ, IL-17a, TNF-α, IL-1β, IL-12p70, Leptin, EGF, VEGF, MCP-1, and
GRO-KC.
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Figure 8. Cytokine and Chemokine Expression in CSF IL-1α was unchanged
from sham or naïve animals compared to Injury or Injury + Veh groups. IL-1α
was decreased with 25 μg E2 treatment, and levels were BLQ for the 2.5 μg E2
treatment (data not shown). IL-6 was increased following injury, and E2
treatment reduced levels to that of sham and naïve animals. IL-10 was
increased with injury; E2 treatment reduced level to sham and naïve animals.
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MCP-1 was significantly increased with injury and reduced significantly with E2
treatment. GRO-KC was increased with injury and significantly decreased with
25 μg E2 treatment. TNF-α was increased with injury and decreased with 2.5 μg
E2 treatment.
p<0.05.

Significant differences between Sham and Inj + Veh groups,

* Significant difference between Injury + Veh group and Injury + 25/2.5

µg E2 treated group, p<0.05. n=5 all groups
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Table 1. Cytokine, Chemokine, and Growth Factor Expression in CSF GCSF, eotaxin, GM-CSF, MIP-1A, IL-5, and MIP2 were below the limits of
quantification (BLQ) in this assay, thus omitted. Values are expressed as: Mean
(SEM). A minimum of 3 samples were required for mean and SEM analysis
(numerous samples were below limit of quantification), thus analytes with less
than 3 were omitted and indicated as such. * P value for Injury + Veh group vs.
Injury + 25 µg E2 treated group. ** P value for Injury + Veh group vs. Injury + 2.5
µg E2 treated group.
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Spinal Cord Tissue Cytokine/Chemokine Profiling: All 27 of the
cytokines/chemokines profiled were assayed at measurable levels. However, GCSF was BLQ for the naïve and 25 μg E2 dose groups. Both IL-6 and GRO-KC
were significantly increased with SCI and significantly decreased at the 2.5 µg E2
dose (Figure 9). MCP-1 was significantly increased with SCI, however E2
treatment only slightly trended for a decrease (Figure 9). Using the screening
approach to evaluate the remaining markers the majority of cytokines showed no
change in level with either injury or E2 treatment. The cytokines that were
unchanged were IL-4, IL-2, IL-13, IL-12p70, IFN-γ, IL-5, IL-17A, and IL-18 (Table
2). Analytes displaying increased levels with injury and decreased levels with E2
treatment were IL-1α, IL-1β, IL-6, IL-10, TNF-α, and leptin (Figure 9, Table 2).
The chemokines eotaxin, fractalkine, and LIX were unchanged in level with injury
or E2 treatment. G-CSF, MIP-1α, MCP-1, GRO-KC, LIX, MIP-2, and RANTES
were increased with injury and decreased with E2 treatment while IP-10 levels
were increased with injury but not affected by E2 treatment (Table 2).

The

growth factors EGF and VEGF were increased with injury and decreased in E2
treated groups (Table 2). The factors that exhibited the greatest change in
expression between sham and injury, suggesting their specificity as biomarkers
of spinal cord injury, were IL-1α, IP-10, GRO-KC and MIP-2. These factors
showed 4-7 fold increases between sham and injury groups. The marker with
the largest increase in expression was MIP-1α, with a 20-fold increase in
expression between sham and injury groups. In summary, data suggest that E2
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treatment at either the 25 or 2.5 μg dose modulate the following
cytokines/chemokines in the spinal cord tissue: IL-1α, IL-1β, IL-6, IL-10, TNF-α,
Leptin, G-CSF, MIP-1α, MCP-1, GRO-KC, LIX, MIP-2, RANTES, EGF, and
VEGF.
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Figure 9. Cytokine and Chemokine Expression in Spinal Cord Tissue IL-1α and RANTES
were significantly increased in Injury + Veh group compared to Sham and significantly decreased
with either dose of E2. IL-6, IL-10, and GRO-KC were significantly increased in Injury + Veh
group compared to Sham, and significantly decreased with 2.5 μg E2 treatment. MCP-1 is
significantly increased in the Injury + Veh group, and treatment with E2 showed a trend toward a
decrease.

Significant difference between Sham and Inj + Veh groups, p<0.05.

*

Significant

difference between Injury + Veh group and Injury + 25/2.5 µg E2 treated group, p<0.05. n=6 per
group
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Table 2: Cytokine, Chemokine, and Growth Factor Expression in Spinal
Cord Tissue All 27 analytes were analyzed. Values are expressed as: Mean
(SEM). Samples in which the “n” was below 6 were due to values that were BLQ
and were omitted. * P value for Injury + Veh group vs. Injury + 25 µg E2 treated
group. ** P value for Injury + Veh group vs. Injury + 2.5 µg E2 treated group.
n=6 all groups
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Plasma Cytokine/Chemokine Profiling: All 27 of the cytokines/chemokines
profiled were assayed at measurable levels. IL-6, GRO-KC, IL-12, IL-17, IFN- γ
and MCP-1 were all found to be significantly decreased with E2 treatment (Figure
10). Surprisingly, the levels of IL-6, GRO-KC, and MCP-1 were comparable
between sham and Injury + Veh animals. Comparison of these markers in naïve
animals reveals that all three markers are increased due to the laminectomy
procedure, suggesting that in plasma these are general markers of inflammation
due to the surgical procedure rather than markers specific to injured spinal cord
tissue (Table 3). Using the screening approach to evaluate the remaining
markers, the majority of cytokines in the plasma showed dynamic responses to
sham, injury, and E2 treatment. IL-1α, IL-4, IL-1β, IL-2, IL-13, IL-10, IL-12p70,
IFN-γ, IL-5, IL-17A, IL-18, and TNF-α were increased with either sham or injury
and decreased with E2 treatment (Table 3). Both growth factors EGF and VEGF
were increased with injury and decreased with E2 treatment, and the chemokines
IP-10, fractalkine, MIP-2, and RANTES were unchanged between injury and E2
treated groups (Table 3). Eotaxin, GM-CSF, and MIP-1α were decreased with
E2 treatment, but unchanged by injury (Table 3). G-CSF and LIX were increased
with injury and decreased with E2 treatment (Table 3). A number of factors
showed large increases in expression between the naïve and sham groups: IL1α, IL-4, IL-1β, IL-6, IL-13, IL-10, IL-12p70, IFN-γ, IL-18 and GRO-KC (55 fold
increase). However, given that the sham treatment (laminectomy without
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contusion injury) does not involve damage to the spinal cord, these markers
could represent systemic response to trauma. Leptin, however, had a 3-fold
increase between sham and injury, making it a potential biomarker specific to
SCI. In summary, data suggest that E2 treatment at either the 25 or 2.5 μg dose
may modulate the following cytokines/chemokines in the plasma after SCI: IL-1α,
IL-4, IL-1β, IL-2, IL-6, IL-13, IL-10, IL-12p70, IFN-γ, IL-5, IL-17A, IL-18, TNF-α,
EGF, VEGF, Eotaxin, GM-CSF, MIP-1A, G-CSF, MCP-1, GRO-KC and LIX.
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Figure 10. Cytokine and Chemokine Expression in Plasma Levels for IL-6,
IL-12, IL-17, MCP-1, IFN-γ, and TNF-α were comparable between Sham and
Injury + Veh groups. IL-6, IL-12, IL-17, MCP-1, and IFN-γ were significantly
decreased with either or both E2 doses. E2 treatment decreased TNF- α to
below that of the naïve group. * Significant difference between Injury + Veh
group and Injury + 25/2.5 µg E2 treated group, p<0.05. n=6 per group
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Analyte

Naïve

Sham

Injury + Vehicle

G-CSF
Eotaxin
GM-CSF
IL-1a
Leptin
MIP-1a
IL-4
IL-1B
IL-2
IL-6
EGF
IL-13
IL-10
IL-12p70
IFNy
IL-5
IL-17A
IL-18
MCP-1
IP-10
GRO/KC
VEGF
Fractalkine
LIX
MIP-2
TNFa
RANTES

47 (9)
25 (9)
99 (40)
31 (6)
1816 (408)
7 (2)
36 (6)
omitted
85 (36)
869 (279)
1.7 (0.6)
82 (18)
39 (11)
353 (93)
1077 (474)
96 (19)
37 (11)
74 (27)
2422 (796)
63 (7)
201 (71)
23 (9)
21 (4)
542 (90)
omitted
25 (9)
186 (14)

201 (53)
90 (9)
245 (57)
234 (54)
1738 (188)
23 (3)
152 (41)
106 (42)
306 (66)
4058 (993)
5.4 (1)
349 (41)
173 (28)
1248 (194)
4351 (540)
215 (21)
121 (28)
331 (79)
6666 (1504)
107 (10)
11001 (1257)
84 (14)
48 (8)
1137 (248)
101 (20)
84 (10)
131 (18)

176 (47)
75 (16)
228 (48)
151 (47)
4047 (1085)
19 (5)
140 (39)
85 (48)
306 (76)
3913 (887)
6.3 (2.4)
239 (70)
150 (34)
975 (265)
3073 (835)
159 (31)
114 (23)
307 (82)
5348 (1442)
98 (14)
8359 (2037)
72 (13)
45 (6)
1186 (303)
109 (30)
67 (16)
151 (35)

Injury + 25 μg E2 Injury + 2.5 μg E2
31 (12)
18 (10)
56 (26)
omitted
11987 (1364)
omitted
13 (7)
omitted
11 (4)
257 (139)
4.9 (3.7)
55 (34)
45 (17)
80 (48)
537 (329)
57 (24)
14 (8)
omitted
1305 (661)
101 (8)
2635 (958)
25 (5)
32 (6)
220 (74)
83 (11)
11 (6)
141 (16)

20 (5)
14 (2)
145 (55)
28 (5)
3407 (1595)
7 (2)
38 (10)
omitted
74 (33)
1249 (403)
1.0 (0.3)
50 (11)
66 (27)
236 (78)
106 (22)
59 (11)
24 (10)
112 (42)
1401 (186)
79 (26)
469 (34)
26 (11)
49 (8)
369 (89)
133 (18)
12 (5)
176 (50)

Uncorrected P Value
* Inj + 25 μg E2
**Inj + 2.5 μg E2

False Discovery Rate
Corrected P Values

*0.03 ** 0.017

*0.008
*0.008
*0.006 **0.025

*0.0464
*0.046 ** 0.093

*0.016 ** 0.017
*0.004 **0.03

*0.072 ** 0.072
*0.046 ** 0.093

*0.009
*0.004 ** 0.015
*0.009 **0.009
**0 .004
*0.004 * 0.009
*0.036
*0.036

*0.046
*0.046 **0.072
*0.046 **0.046
** 0.114
*0.046 **0.046
*0.1061
*0.1061

** 0.009
*0.004 ** 0.031

** 0.046
*0.046 ** 0.01

*0.004 ** 0.03

*0.046 **0.01

*0.008 ** 0.032

*0.046 **0.01

Table 3. Cytokine, Chemokine and Growth Factor Expression in Plasma All
27 analytes were analyzed. Values are expressed as: Mean (SEM). Samples in
which the values that were BLQ were omitted. * P value for Injury + Veh group
vs. Injury + 25 µg E2 treated group. ** P value for Injury + Veh group vs. Injury +
2.5 µg E2 treated group. n=6 per group
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Western Blot S100β
There was a significant increase in S100β protein levels in spinal cord tissue of
Inj + Veh group (195% of control) vs. Sham (100% of control) (Figure 11). There
was a non-significant reduction of S100β in the Inj + 25 µg E2 vs. Inj + Veh
(153% of control vs. 195% of control) , however, a significant reduction was
seen in S100β protein expression in the Inj + 2.5 µg E2 group vs. Inj + Veh (89%
of control vs. 195% of control) (Figure 11). The Inj + 2.5 µg E2 group had S100β
levels comparable to those seen in sham.
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Figure 11. S100β Expression in Spinal Cord Tissue A significant increase in
S100β was found in the Injury + Veh group as compared with Sham, and a
significant decrease was seen with the 2.5 μg E2 dose. Two representative
bands per group displayed (n=6 per group total). # Significant differences
between Sham and Inj + Veh groups, p<0.05, *Significant difference between
Injury + Veh group and Injury + 25/2.5 µg E2 treated group, p<0.05
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Discussion
Given safety concerns associated with high doses of E2 (thrombus,
feminization, stroke, etc.), a nanoparticle drug delivery system was utilized. We
report that by using an E2 nanoparticle embedded gel approach the
concentration of E2 in the spinal cord tissue is double that of plasma (Figure 1).
Additionally, the plasma concentration at the 2.5 µg E2 dose resulted in plasma
levels of 81 pg/mL (Figure 1). These levels are well within physiological range
(peak non pregnant plasma E2 levels in females are 300 pg/mL (Saddick 2014)).
Therefore, E2 delivered focally to damaged tissue may be efficacious at
physiological plasma levels. This approach retains significant translational
relevancy, as the majority of acute SCI individuals will undergo spine stabilization
surgery, thus providing opportunity for surgical placement of a therapeutic gel
patch.
The approach of sampling 3 biological compartments with naïve controls
has allowed for a further understanding of how inflammatory signals correspond
between plasma/CSF/tissue in both SCI and in surgical intervention
(laminectomy). Notably, the plasma levels of IL-6, GRO-KC, and MCP-1 are
comparable between sham and injury + vehicle groups (Figure 2), while naïve
controls are significantly lower (Table 3). These results suggest that the
laminectomy procedure alone can result in the same response of IL-6, GRO-KC,
and MCP-1 in plasma, and suggest that IL-6, GRO-KC and MCP-1 may be
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primarily derived from a peripheral source rather than injured nervous tissue.
The pattern of IL-6, GRO-KC and MCP-1 in tissue and CSF are very different
from plasma, however.

In tissue and CSF sham levels are lower than injury +

vehicle animals, revealing specificity for injury within these compartments (Figure
2). Given the specificity of the CSF for increased IL-6, GRO-KC, and MCP-1
only in the presence of spinal cord injury, the data suggest the pool of IL-6, GROKC, and MCP-1 measured in CSF is derived, in part at least, from the damaged
spinal cord. As human studies must extrapolate how the CSF or plasma relates
to the state of the injured spinal cord, the data presented here provide a
comprehensive profile of acute inflammatory signaling in 3 compartments to
allow for a greater understanding of how plasma and CSF reflect tissue response
to injury across 27 cytokines/chemokines (Tables 1-3). As IL-6, GRO-KC, and
MCP-1 have been previously identified in human studies as candidate
biomarkers in CSF (Kwon, Stammers et al. 2010) these data, in a “reverse
translational” approach, help provide evidence that the markers are reflective of
the condition of the injured spinal cord.
E2 treatment resulted in rapid anti-inflammatory effects, and these effects
were seen at both doses chosen for the present study (25 μg or 2.5 µg.) In
particular, the study focused on IL-6, GRO-KC, MCP-1, and S100β as these
markers have been previously identified in human studies as either being
elevated in injury or as potential biomarkers of injury severity (Kwon, Stammers
et al. 2010, Bank, Stein et al. 2014, Pouw, Kwon et al. 2014). E2 treatment
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significantly decreased IL-6 expression in plasma and tissue, and trended
towards a decrease in CSF (Fig. 2). IL-6, a prototypical cytokine, is rapidly
secreted at the site of injury by a number of cell types including neurons, glia, Tcells, and macrophages, and plays a central role in early neuroinflammatory
response (Erta, Quintana et al. 2012). E2 pretreatment has previously been
reported to decrease tissue levels of IL-6 at a 24hr time point in a mouse model
of SCI (Cuzzocrea, Genovese et al. 2008). However, Ritz and Hausmann
reported that a 0.1 mg/kg or 4 mg/kg E2 dose in an acute rat SCI model
significantly increased IL-1α, IL-1β, and IL-6 in tissue at 6hrs post treatment (Ritz
and Hausmann 2008). Differences in dosages, dose routes, and time points may
explain the incongruous results with E2 regulation of IL-6 in acute SCI.
The neutrophil attractant chemokine, GRO-KC (rodent IL-8 homolog),
has been reported to be increased in acute SCI (McTigue, Tani et al. 1998,
Stammers, Liu et al. 2012). Neutrophils, one of the first peripheral immune cells
to migrate to the lesioned tissue, are thought to be key contributors to the
secondary injury seen in SCI (Neirinckx, Coste et al. 2014), and further, a
reduction of infiltrating neutrophils has shown decreased tissue damage in a rat
model (Bao, Fleming et al. 2011). In a traumatic brain injury model GRO-KC has
also been associated with blood brain barrier dysfunction and nerve growth factor
production, making it a potentially important chemokine in neurotrauma and
repair (Kossmann, Stahel et al. 1997). Thus, GRO-KC (IL-8) may be a critical
chemokine to regulate in acute SCI. Here, we report that E2 treatment
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significantly reduced GRO-KC in the plasma and tissue compartments with a
trend for reduction in the CSF (Figure 2), again highlighting the therapeutic
potential of E2 in acute SCI.
MCP-1 (CCL2) is a small chemokine induced by a variety of stimuli (injury,
inflammation, oxidative stress, etc.) that is produced by a variety of cell types and
functions to recruit monocytes/macrophages to the site of injury or inflammation
(Deshmane, Kremlev et al. 2009). Studies have found a correlation between
macrophage infiltration and MCP-1 levels (Lee, Shih et al. 2000), and MCP-1 has
been found to be upregulated in animal models following SCI (Lee, Shih et al.
2000). In a naturally occurring canine SCI, MCP-1 levels in CSF were negatively
associated with post-injury outcome (Taylor, Welsh et al. 2014). Here we report
that E2 treatment resulted in a significant decrease in MCP-1 levels in plasma
and CSF, while tissue levels had a slight trend only for decrease (Figure 2). A
link has been shown between estrogen receptor α (ERα) and MCP-1 expression.
In an experimental autoimmune encephalitis model treatment with ERα specific
ligand resulted in decreased MCP-1 (Spence, Wisdom et al. 2013). Given these
prior findings, these data further support the hypothesis that E2 may decrease
inflammation through regulation of MCP-1 signaling.
The calcium binding protein S100β, most abundantly found in glial cells,
is involved in a number of cellular processes including: inhibition of protein
phosphorylation, regulation of cell-cycle progression, astrocyte proliferation, and
can act in a concentration dependent manner as either a trophic or toxic factor to
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neurons (Donato 1999). A direct link between E2 and S100β expression is not
yet known. E2 has been reported to decrease calcium influx through interaction
with L-Type voltage gated calcium channels in an in vitro setting of glutamate
excitotoxicity (Sribnick, Del Re et al. 2009). Given S100β is a calcium binding
protein a direct or indirect relationship may exist where E2’s modulation on
calcium influx would influence S100β expression and/or release. However, it
should be noted that S100β is a highly complex signaling protein with the
potential to serve widely varying functions in intracellular or extracellular roles
that are also dependent on disease state (Donato, Sorci et al. 2009). Given the
complexity of both E2 and S100β it may be overly simplistic to hypothesize
calcium as the link between the two as numerous additional pathways may be
involved. Regardless of this complexity as a signaling molecule, the role as a
biomarker has been shown in numerous animal models of SCI where S100β is
elevated in serum and/or CSF of injured animals compared to sham (Ma,
Novikov et al. 2001, Loy, Sroufe et al. 2005, Cao, Yang et al. 2008).

In

addition, S100β has been identified in two human SCI as a candidate biomarker,
capable of predicting injury severity into either a specific ASIA rating (Kwon,
Stammers et al. 2010) or complete vs. incomplete injuries (Pouw, Kwon et al.
2014). Given the growing evidence that S100β may be a valid biomarker for
injury severity in human SCI, our findings that E2 nanoparticle treatment
significantly decreased S100β expression in spinal cord tissue (Figure 3) suggest
that early intervention with E2 may decrease injury severity. Due to the small
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volume of CSF that can be collected from a rat analyzing both
cytokine/chemokine screens and S100β levels was not possible; however, this
warrants further investigation.
While IL-6, GRO-KC, MCP-1, and S100β were the focus of the study the
multiplex assay format allowed for an additional screen to be performed for the
potential identification of new E2 targets. Using a Wilcoxon rank sum test to
screen all 27 markers evaluated it was found that E2 treatment exerted
widespread effects on cytokines/chemokines/growth factors such as: leptin, MIP1α, IL-4, IL-2, IL-10, IFNγ, TNFα, etc . More specifically, 15 analytes were
significantly decreased in plasma (Table 3), 6 analytes were significantly
decreased in spinal cord tissue (Table 2), and a number trended to be decreased
in CSF (Table 1). The lack of significance in the CSF compartment may be
attributed to increased variance in these samples as compared with tissue or
plasma. These findings further highlight the pleiotropic nature of E2 in the
setting of neurotrauma and suggest that the rapid anti-inflammatory signaling
exerted by E2 may contribute to the improvement in motor function as previously
reported (Cuzzocrea, Genovese et al. 2008, Ritz and Hausmann 2008, Sribnick,
Samantaray et al. 2010, Samantaray, Smith et al. 2011, Lee, Choi et al. 2012,
Mosquera, Colon et al. 2014).

It remains to be seen whether low dose

nanoparticle delivered E2 may result in functional improvement. However, as we
continue to evaluate this method of E2 delivery in functional models of SCI, we
will seek a better understanding of how early anti-inflammatory treatment may
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modulate late-stage motor recovery. Thus, by using this targeted nanoparticle
drug delivery approach, we hope to advance the highly promising therapeutic E2
into clinical studies, ultimately allowing for development of a safe and effective
treatment for acute SCI individuals.
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CHAPTER THREE
E2 AS A NEUROPROTECTANT AT 48HRS FOLLOWING SCI AND
TIME COURSE STUDY OF E2 RELEASE FROM NANOPARTICLE

68

INTRODUCTION
Nanoparticle delivery of E2 to damaged spinal cord tissue may allow for
sustained drug release such that drug effects may be seen not only in peracute
models (hours of injury) of inflammation but also for days following as the
nanoparticle continues to deliver drug. This method of drug delivery may be
optimal due to several factors: single administration, focal administration, and
prolonged release. Traditional dose routes such as IV or IP do not allow for any
of these advantages. Additionally, these dose routes will result in very high plasma
concentrations at early time points, furthering the risk of toxicities. Nanoparticle
E2 delivery may reduce those maximal exposures seen conventionally while
prolonging plasma exposure, making it appropriate for treatment of acute SCI.
Given this approach requires the surgical application of the nanoparticle gel plug
during spine stabilization/decompression surgery (typically within 6-8 hrs of injury),
the drug chosen should be optimized for lessening secondary injury mechanisms.
The highly pleiotropic nature of E2 makes it an ideal candidate for treatment of
complex pathologies such as those seen in secondary injury.

Nanoparticle

delivery of E2 may further enhance therapeutic potential for increases in neuronal
protection and recovery through numerous mechanisms, including increased
neurotrophin expression, decreased inflammation and gliosis, and increased
neuronal survival. While these are certainly not the only potentially mechanisms,
angiogenesis for example is another mechanism by which E2 may exert protective
effects (Chen, Yeh et al. 2010), these will be the focus of the work presented
herein.
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Growing evidence supports a link between E2 and neurotrophin regulation, for
example an E2 responsive element was identified on the brain derived
neurotrophic factor (BDNF) gene suggesting a direct regulatory link (Sohrabji,
Miranda et al. 1995). As neurotrophins are largely produced by glial cells to signal
for neuronal survival and health, a study of how neurotrophins may be regulated
by E2 in glia cells is warranted. In cultured astrocytes, E2 receptor alpha has been
shown to regulate expression of GDNF, BDNF, and nerve growth factor (NGF)
(Xu, Bi et al. 2013).

Incubation of astrocyte-neuron co-cultures with 100nM E2

has been reported to result in upregulation of GDNF, specific to astrocytes
(Campos, Cristovao et al. 2012). Treatment of an in vivo model of traumatic brain
injury with Premarin has been reported to upregulate GDNF and was shown by
double immunostaining to co-localize with bromodeoxyuridine (Brdu) expressing
neurons in hippocampus, suggesting a role in neurogenesis (Chen, Yeh et al.
2010).

Given these preliminary findings, we hypothesize that E2 may stimulate

an increase in neurotrophins, such as GDNF, in the injured spinal cord.
Inflammation is a natural response to tissue damage and serves a physiological
purpose to contain and repair injured tissue. However, excessive inflammation, as
seen in neurotrauma, leads to increased injury severity as described in the
secondary injury theory (Tator and Fehlings 1991).

One of the potential

mechanisms contributing to the spread of secondary injury, also a central
mechanism to inflammation, is reactive gliosis. Gliosis is a generic term that
describes activation of any type of glial cell, including astrocytes, microglia, and
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oligodendrocytes.

Reactive astrogliosis was thought for many years to be a

maladaptive response as the primary driver of glial scarring, and thus the blockade
of axonal regeneration in SCI. For years this dogma existed, and prevention of
this response became a research focus. This polarizing view has now been
disproven as many transgenic models reveal detrimental effects by complete
blockade of astrocyte response, as reviewed elsewhere (Sofroniew 2009).
Astrocytes contribute to gliosis in both beneficial and detrimental ways through
complex signaling mechanisms, as described in a recent review (KarimiAbdolrezaee and Billakanti 2012).

The release of proinflammatory cytokines

TNF-α, IL-1β, and IL-6 during the acute phase of tissue injury may be the key
signaling trigger in the activation of astrocytes, as recently reported (Lin, Basu et
al. 2006, Karimi-Abdolrezaee and Billakanti 2012). Given our findings that E2 can
acutely decrease an array of proinflammatory cytokines and chemokines including
TNF-α, IL-1β, and IL-6 in both systemic and local compartments we hypothesize
that E2 treatment will result in decreased astrogliosis.

Astrogliosis is pathologically characterized by hypertrophied (as characterized
by extended and swollen processes) and proliferated astrocytes in and around
lesioned tissue. The hallmark molecular marker of activated astrocytes is glial
fibrillary acidic protein (GFAP), an intermediate filament protein required for
cytoskeletal modifications such as hypertrophy that mark astrogliosis (Sofroniew
and Vinters 2010). Other markers such as glutamine synthase and S100β have
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also been proposed as markers specific to activated astrocytes, respectively
(Norenberg 1979, Barres 2008, Goncalves, Leite et al. 2008).
Glutamine synthase is a critical enzyme in the conversion of glutamate and
ammonia to glutamine within the astrocyte; this recycling allows for protection
against glutamate excitotoxicity. The enzyme has been found to be upregulated in
astrocytes following spinal cord injury, further illustrating its potential as a marker
of astrogliosis (Benton, Ross et al. 2000). However, production of glutamine
synthase has been reported in microglia, macrophages, and oligodendrocytes in
rat spinal cord; however, only astrocyte and macrophage/microglia produced
glutamine synthase contributed to increased levels following injury (Liu, Wu et al.
2013). Given these findings, glutamine synthase may be considered a marker of
gliosis, rather than specific to astrogliosis.
Excitotoxicity, the pathological overstimulation of glutamate receptors, is a
major contributor to neuronal death following acute injury (Mazzone and Nistri
2014). Thus, it is critical for a potential neuroprotectant to decrease excitotoxicity,
thereby sparing neuronal loss. Immediately following SCI there is a rapid rise in
the excitatory neurotransmitter glutamate to concentrations high enough to drive
neuronal death (Liu, Thangnipon et al. 1991). Glutamate receptors may be broadly
classified into two groups, either metabotropic or ionotropic. Ionotropic receptors,
more specifically the NMDA receptor, function by forming an ion channel after
glutamate binding, and allow for the rapid movement of ions into the cell.

The

NMDA receptor, once activated, may result in a lethal calcium influx into the cell,
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resulting in cell death (Choi 1992). Riluzole (a sodium channel blocker / glutamate
receptor modulator discussed in Chapter 1) has recently been evaluated in a
Phase I safety and preliminary efficacy trial and reported to have significantly
enhanced motor function, particularly among cervical injury patients (Grossman,
Fehlings et al. 2014).

These results are very promising and suggest the

importance of modulating excitotoxicity in the acute stage of SCI. As discussed
previously, E2 treatment has been shown to decrease glutamate induced cell
death by inhibiting calcium influx through the L-type voltage gated calcium channel
(Sribnick, Ray et al. 2006). We hypothesize that E2 treatment may decrease
glutamine synthase expression through indirect mechanisms involving the
decrease of glutamate signaling, thereby decreasing excitotoxicity.
S100β has been identified as an early biomarker of excitotoxicity released by
astrocytes (Mazzone and Nistri 2014). As discussed earlier, S100β, is a calcium
binding protein and a complex signaling molecule active in homeostasis as well as
disease (Donato 1999).

In a pathological setting S100β protein may play a

detrimental role. Treatment of cultured astrocytes and neurons with a high
concentration of S100β revealed inducible NOS activation, NO production, and
subsequent neuronal death (Hu, Ferreira et al. 1997).

Currently, no literature

exists directly linking S100β and E2 regulation, hence we aim to further explore
the potential for E2 to change S100β signaling in SCI.
Microglia, as the resident immune cell of the CNS, also play an active role in
gliosis following injury.

Activated microglia express ionized calcium binding
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adaptor molecule 1 (Iba1), which has been reported to be exclusively produced in
microglia, making it an ideal marker for measurement of microglia activity (Ito, Imai
et al. 1998). Based on its molecular structure Iba1 is hypothesized to serve as an
adaptor molecule mediating calcium signals (Ito, Imai et al. 1998). Given E2 may
decrease calcium influx, we hypothesize that E2 treatment will reduce IBa1
expression in microglia.

By decreasing microglial activation, the potential to

decrease the downstream effects of microglia signaling follow.
Microglia secrete factors such as nitric oxide (NO) and cyclooxygenase (COX2) that serve to trigger inflammation (Chao, Hu et al. 1992, Giulian, Corpuz et al.
1993).

Nitric oxide (NO), a gas and free radical, is an important signaling

molecule across the body that serves as a potent vasodilator, neurotransmitter,
and also as a free radical that can cause oxidative damage to surrounding tissue.
NO is produced by a variety of nitric oxide synthases. In inflammation the isoform
inducible nitric oxide synthase (iNOS) is the primary enzyme responsible for its
production. It is reported that iNOS production is increased in lesioned spinal cord
tissue and that decreasing iNOS activity results in improvements in locomotor
activity in a rat model (Jiang, Gong et al. 2014). In addition E2 administration in a
mouse model (300µg/kg subcutaneous pre and post-injury induction) was shown
to significantly decrease iNOS expression, resulting in improved locomotor
recovery (Cuzzocrea, Genovese et al. 2008). COX-2, an enzyme responsible for
the conversion of arachidonic acid to prostaglandins, is another biochemical
marker of inflammation. COX-2 is upregulated in a rat model of SCI, and blockade
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results in improved locomotor function recovery (Resnick, Graham et al. 1998,
Cuzzocrea, Genovese et al. 2008).
To further understand the multi-faceted role that E2 may play as a
neuroprotectant in SCI, various proteins will be investigated at the 48hr time point.
E2 driven effects on proteins related to the neurotrophin GDNF, inflammation
(COX-2 and iNOS), glial response (GFAP, Iba1, glutamine synthase, S100β), and
apoptosis (BAX and Bcl2) will be studied via Western blot (WB) and
immunofluorescence (IF) techniques. The apoptotic markers are chosen given the
48hr time point is the stage in which early apoptosis and changes in injury related
proteins can be seen, and therefore any potential therapeutic effects of E2
treatment may be uncovered. In summary, we hypothesize that by delivering E2 in
a nanoparticle gel embedded formulation, we will show a prolonged release into
the plasma compartment as compared with conventional drug dosing techniques
(IV or IP) resulting in improved neuroprotection.
MATERIALS AND METHODS
Nanoparticles and Gel Plug Delivery System: Techniques will be the same as
described in Chapter 2.
Rat SCI Model:48Hr Rat SCI Model: Induction of injury and treatment with E2
nanoparticle will be conducted exactly as described for the 6hr model, with the
exception being time point for sacrifice will be extended to 48hrs. For western
blots n=5 per injury group, n=3 for sham group; and for immunofluorescence
experiments n=3 all groups.
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Rat Plasma Concentration Time Course Model: Naïve animals with no
laminectomy were used for the IV and IP dose groups. For the nanoparticle
embedded gel plug delivery a SCI was performed to allow for placement of gel
plug onto lesioned tissue. All groups will have n=3, rats were serially bled via tail
vein under isoflurane anesthesia.
E2 Delivery: Intravenous and Intraperitoneal Injections
For IP injections animals were injected with 25 µg 17-β estradiol dissolved in corn
oil (100 ug/mL, 25 uL dose) as a single bolus dose. For IV dosing animals were
injected via tail vein with 25 µg water soluble 17-β estradiol (sigma E4389, 100
µg/mL, 250 uL dose) as a single bolus dose. IV injections were done under
isofluorane anesthesia.
In Vivo: Plasma Collection 48 hr profile studies
Whole blood drawn via tail vein puncture was collected into EDTA containing
tubes (final concentration EDTA 1.5 mg/mL).

Samples were collected at 1, 2, 4,

8, 12, 24, and 48 hrs following drug administration. Animals were serially bled,
(n=3 per group) such that each animal underwent 7 tail vein bleeds, and one final
cardiac stick. Whole blood samples were spun at 10,000 RPM in a Sorvall
Legend Micro21 bench top centrifuge, and plasma was collected and stored at 80°C. 17-β estradiol (E2) concentration was determined using a commercially
available ELISA kit (Calbiotech Estradiol ELISA ES180S).
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Tissue Collection and Analysis: As described above, spinal cord samples will be
harvested into three segments and either snap frozen for protein analysis on WB
(n=5) or embedded into OCT and frozen for cryostat sectioning and IF (n=3).
Western Blotting: For this analysis, an additional group, laminectomy + injury
(injury), will be included. This will allow for comparison to Injury + Veh group and
determination if the agarose gel or saline loaded nanoparticles exert any biological
effects. Additionally, only the 25 µg E2 dose group will be analyzed by western
blotting. Samples will be homogenized with hand held Polytron in homogenizing
buffer with protease inhibitors. Bradford assay will be performed for protein
estimation, and normalized samples will be diluted to 2.0 µg/µL concentration with
sample buffer [62.5 mM Tris–HCl, pH 6.8, 2% sodium dodecyl sulfate, 5 mM βmercaptoethanol, 10% glycerol] and boiled for denaturation. Samples will be
loaded onto 10-20% polyacrimide gels for SDS-PAGE using 4-20% precast gels
(Bio-Rad Laboratories, CA, USA) and resolved at 100 V for 1 and 1/2 hrs.
Immunoblotting was performed as described in a previous lab publication
(Samantaray, Patel et al. 2013). The resolved gel was transferred to Immobilon™polyvinylidene fluoride microporous membranes (Millipore, MA, USA). The
membranes were blocked for 1 hr with non-fat dry milk powder in wash buffer
(0.1 % Tween-20 in 20 mM Tris–HCl, pH 7.6). Immunoblotting was then performed
with primary antibodies: COX-2 (Cell signaling #12282), BAX (sc-7480), Bcl2 (sc130308) GDNF (ab18956), and glutamine synthase (MAB302). Results from WB
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will be analyzed via Friedman’s method two-way ANOVAs on GraphPad Prizm
software.
Immunofluorescence:

Spinal cords (caudal penumbra) were sectioned on a

cryostat at 8µM and mounted onto slides. For all stains, slides were treated using
this basic protocol:
(1). Fixation for 15 minutes in either 95 % EtOH or -20⁰ C acetone (2). Washed 3
x 5 minutes in PBS (3). Blocked in 2% serum protein of the host secondary for 2
hrs at RT. (4). Incubated overnight in primary antibody, 20⁰ C. (5). Washed 3 x 5
minutes in PBS (6). Incubated secondary antibody 2 hrs at RT (7). Washed 3 x 5
minutes in PBS (8). Final wash in deionized water 5 minutes (9). Allow to air dry,
mount with ProLong Gold anti-fade mounting media with DAPI (Life Technologies
#P36931), and coverslip. The primary antibodies used are summarized in the
table below.

Antibody

Target Cell

Source

GFAP

astrocyte

MAB3402

S100 β

astrocyte injury

ab52642

GDNF

glial

ab18956

ED-1

macrophage

ab31630

Iba-1

microglia

ab5076

Table 4. Antibodies and Targets in Immunofluorescent Staining Antibodies,
targets, and source information for all of the immunofluorescent staining
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Immunofluorescence Signal Intensity Analysis: GFAP, S100β, Ed-1, and Iba-1
antibody stains were analyzed for signal intensity. All images were captured at
20X magnification on an Olympus IX73 inverted fluorescent microscope. Images
were taken in the dorsal funinculus, and all images for a given stain were captured
on a single day under identical settings. A single image was taken of each animal
per group such that n=3 images per group for analysis. Fluorescent intensity was
measured using Image J software to determine fluorescent pixel intensity per field,
and reported as arbitrary units. Statistical differences were determined by oneway ANOVAs with a Tukey’s post-test using GraphPad Prizm software.
RESULTS
48 E2 Plasma Profiling of 25 µg and 2.5 µg E2 Nanoparticle Doses:
The maximum concentration (Cmax) for the 25 µg dose was 500 ± 154 pg/mL and
time at which maximal plasma concentration (Tmax) occured was 4hrs following
administration. The Cmax for the 2.5 µg dose was 172 ± 99 pg/mL and the Tmax
was 2hrs. By 24 hrs both dose groups had returned to plasma E2 levels seen in
non-treated rats.
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Figure 12. E2 Time Course Plasma Concentration 25 and 2.5 µg E2

SCI

rats treated with 25 μg or 2.5 µg dose of E2 nanoparticle embedded gel plug
(n=3 per group).
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48hr E2 Plasma Profiling of IV, IP, and Nanoparticle Drug Delivery Approaches:
Comparison of different dosing techniques highlights the differences in plasma
exposures. The Cmax / Tmax for the IV group was 1064 ± 250 pg/mL / 1hr, the IP
group was 324 ± 114 pg/mL / 1hr, and 500 ±154 pg/mL / 4hrs for the nanoparticle
group. Both the IV and IP dose groups had a Tmax at 1 hr and then the plasma
exposure rapidly decreases, as expected for this dosing technique.

The

nanoparticle group, however, had a delayed Tmax of 4 hrs, and increased plasma
levels out to 12 hrs. This provides evidence of prolonged E2 exposure in the
plasma with decreased maximum concentrations using the nanoparticle delivery
technique.
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Figure 13. Varying Dose Routes and E2 Time Course Plasma Concentration
All groups dosed with 25 μg E2 delivered by single IP, IV, or nanoparticle
embedded gel plug (n=3 per group).
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Western Blotting and Immunofluorescence: GDNF
GDNF expression was found to be significantly increased with E2 treatment in the
caudal penumbra section of the injured spinal cord. No difference was found
between the Injury and Injury + Vehicle treated groups, indicating that the void
nanoparticle embedded agarose gel plug did not exert any effects on this marker.
There was a slight, although not significant, increase in GDNF in the injury group
vs. Sham. Immunofluorescent imaging revealed correlative findings where an
increased in immunoreactivity was found in E2 treated sections as compared with
vehicle treated.

83

Figure 14. GDNF 48hrs (A). WB of GDNF shows a significant increase in GDNF in E2 treated
group. *p<0.05 Injury + E2 nano vs. Injury (B). Immunofluorescence of GDNF imaged in dorsal
funinculus (white matter) of caudal penumbra. Images taken at 200x, representative of group
average. n=3 per group
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Western Blotting and Immunofluorescence: Glutamine Synthase
Glutamine synthase activity was increased with injury and significantly decreased
with E2 treatment. No difference was found between the Injury and Injury + Vehicle
treated groups, indicating that the void nanoparticle embedded agarose gel plug
did not exert any effect on glutamine synthase. Immunofluorescent imaging
revealed correlative findings, where an increased in immunoreactivity was found
in the Injury and Injury + Vehicle groups as compared with the E2 treated sections.
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Figure 15. Glutamine Synthase 48hrs (A). WB of glutamine synthase shows a
significant decrease in the E2 treated group. *p<0.05 Injury + E2 nano vs. Injury (B).
Figure
Immunofluorescence images of glutamine synthase in dorsal funinculus (white matter) of
caudal penumbra illustrate the increase seen in the Injury Vehicle group vs. E2 and sham
groups. Images taken at 200x, representative of group average. n=3 per group
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Western Blotting:Cox-2 & Bax/Bcl-2: Cox-2 expression was upregulated nearly
2.5 fold in the Injury group vs. Sham. Cox-2 was significantly decreased with E2
treatment. Bax expression was increased with Injury, and Bcl-2 protein was
decreased as compared with sham. The resulting ratio in the Injury and Injury +
Vehicle groups is high, illustrating high BAX and low Bcl-2. E2 treatment
reduced the amount of BAX and increased Bcl-2, resulting in a ratio below that of
sham.

Data suggest decreased apoptosis with E2 treatment.
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Figure 16. COX-2 48hrs (A). WB of COX-2 shows 2.5 fold increase in the Injury
groups vs. Sham. E2 treated group shows significantly decreased COX-2
expression. *p<0.05 Injury + E2 nano vs. Injury (B). Blot image taken of 2-3
Western Blotting: BAX/Bcl-2
representative bands of each group. n=3 in sham group, and n=5 in injured
The ratio of the pro-apoptotic protein BAX to the anti-apoptotic protein Bcl-2 was
groups
analyzed as an index of apoptosis. The amount of BAX protein was increased
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Figure 17. Bax / Bcl-2 48hrs (A). WB of Bax / Bcl-2 ratio shows 30% increase
with injury and a 30% reduction below sham treatment with E2 treatment.
*p<0.05 Injury + E2 nano vs. Injury (B). Blot image taken of 2-3 representative
bands of each group. n=3 in sham group, and n=5 in injured groups
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Immunofluorescence Analysis: GFAP
GFAP staining was increased in all Injury groups and found to be significantly
decreased at both doses of E2. Additionally, distinct differences were observed
in the morphology of the reactive astrocytes. An abundance of hypertrophied
astrocytes with large swollen processes were seen in the Injury + Vehicle groups,
as compared with E2 treated. It should be noted, however, that hypertrophied
astrocytes were also seen in the E2 groups, although not as prevalent as in the
Injury + Vehicle groups.
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Figure 18. GFAP Immunofluorescent Staining (A). GFAP (green) and DAPI
(blue) nuclear staining of astrocytes in the dorsal funinculus. Panel of
representative images taken at 60x magnification. (B). Quantification of
fluorescent staining intensity *p< 0.05 E2 group vs. Inj + Veh. n=3 per group
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Immunofluorescence Analysis: S100β
S100β staining was increased in all Injury groups and found to be significantly
decreased at the low dose of E2. The high dose of E2 trended to decrease
S100β immunoreactivity. It is unclear as to why the high dose did not exert more
of an effect on S100β.
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Figure 19. S100β Immunofluorescent Staining (A). S100β (Pink) and DAPI
(blue) nuclear staining of astrocytes in the dorsal funinculus. Panel of
representative images taken at 60x magnification (B). Quantification of
fluorescent staining intensity *p< 0.05 E2 group vs. Inj + Veh. n=3 per group
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Immunofluorescence Analysis: Iba-1
Staining of Iba-1 was increased in all Injury groups, and trended to be decreased
with E2 treatment. The lack of significance in both groups may be attributed to
high variance in the Injury + Vehicle group, and given this images were not
captured.
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Figure 20. Immunofluorescence analysis of Iba-1. Iba-1, an activated
microglia marker, shows elevation with Injury + Vehicle group, and trended for
decrease with E2 treatment. n=3 per group
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Immunofluorescence Analysis: ED-1
Staining of ED-1 was increased in the injured groups as compared with sham.
Increased ED-1 positive cells are expected in lesion tissue at 48 hrs. E2
treatment at either dose significantly decreased ED-1 staining, indicating a
decrease in either infiltrating macrophages or resident tissue macrophages.
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Figure 21. ED-1 Immunofluorescent Staining (A). ED-1 positive (red)
macrophage staining in dorsal funinculus. (B). Immunofluorescence analysis of
ED1. * p<0.05 E2 treated groups vs. Inj + Veh. n=3 per group
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DISCUSSION:

Dose response time course studies measuring E2 levels in plasma
revealed an increased concentration in the 25 µg dose group as compared to the
2.5 µg dose group. The maximum concentration was nearly 3X higher in the
high dose group than the low at the Cmax (Figure 12). Given the data collected
at 6 hrs suggested dose linearity, we had hypothesized dose linearity (10X
difference in concentration) throughout this time course study. However, a range
between 2x-3x increased E2 plasma concentration in the high dose group was
observed. Also, it is important to note that at the 2.5 µg dose maximal plasma
levels remained below those reported to occur in normal rat physiology
(approximately 300pg/mL in pregnant rat) (Saddick 2014). Given that the 25 µg
dose group showed supraphysiological E2 plasma concentration, this dose will
no longer be investigated as the goal of this work is to maintain safe,
physiologically relevant dosing of E2.
Dose administration studies highlighted the differences in plasma levels of
E2 resulting from different dosing routes. IV dosing results in very high peak
plasma exposure (1064 pg/mL, Figure 13). Arguably, this value may be much
higher, as the first time point sampled was at 1HR.

IV dosed drugs typically

have a Cmax that occurs nearly instantaneously, as any drug that is
predominately metabolized through the liver will undergo extensive first pass
metabolism as the blood first clears the liver. Avoiding high E2 plasma
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concentrations is critical in the treatment of SCI, in order to minimize risk of
thromboembolism. Higher doses of E2 used for contraception have been shown
to correlate with increased risk of stroke, and transdermal delivery of E2 confers
lower risk of stroke due to lower maximal blood E2 concentration (Speroff 2010).
Intraperitoneal dosing of E2 in corn oil resulted in very low Cmax (324
pg/mL) and rapid clearance where levels dropped to physiological concentrations
between 4 and 8 hours (Figure 13). Nanoparticle delivery of E2 resulted in
moderate Cmax (500 pg/mL) and a slower clearance, as demonstrated by the
plateau shape of the curve (Figure 13). Of particular note is the change in Tmax
between dose groups. Both the IV and IP groups have a Tmax of 1 hr while the
nanoparticle group has a Tmax of 4hrs (Figure 13). This highlights the potential
of nanoparticles to slowly release E2, thereby allowing for extended plasma
exposure while avoiding a high Cmax.
The glial cell response to injury has been shown to be modified by E2
treatment. The neurotrophin GDNF has been suggested in the literature to be
affected by E2 (Chen, Yeh et al. 2010, Campos, Cristovao et al. 2012, Xu, Bi et
al. 2013). Here, we report an upregulation of GDNF 48 hrs after E2 treatment
(Figure 14). Using immunofluorescence we found GDNF positive cells in the
dorsal funinculus of the spinal cord, in a mixed glial cell population. Increased
GDNF production may contribute to neuronal survival since GDNF injected into
lesioned spinal cord tissue was reported to result in increased neuronal survival
through activation of mitogen-activated protein kinase pathway and upregulation
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of the anti-apoptotic protein Bcl-2 (Cheng, Wu et al. 2002). Here, we also report
an increase in Bcl-2 (Figure 17) that coincides with an increase in GDNF
expression (Figure 14). A study has shown that administration of exogenous
Bcl-2 resulted in increased neuronal survival (Nesic-Taylor, Cittelly et al. 2005).
These data support the hypothesis that E2 is acting as a neuroprotectant through
mechanisms including GDNF upregulation of Bcl-2.
Reactive gliosis has been described as “a constitutive, graded, mulitstaged, evolutionarily conserved defensive astroglial reaction” (Pekny,
Wilhelmsson et al. 2014). The biological response is known to be both beneficial
and maladaptive, especially in SCI where reactive gliosis causes glial scarring
and prevention of regeneration of axons across the scar. However, the complete
removal of reactive gliosis, as shown in various transgenic models, has been
shown to be detrimental, as reviewed elsewhere (Sofroniew 2009). Thus, a
modulation of gliosis may be preferential. As GFAP and S100β are two of the
hallmarks of gliosis, both were examined in astrocytes in the dorsal funinculus of
the caudal penumbra (Figures 18 & 19). Both markers were significantly
decreased with E2 treatment, however, E2 treatment at either high or low dose
did not completely restore levels to sham. E2 treatment therefore only
dampened gliosis, potentially allowing for improved recovery.

Activated

astrocytes are one cell type that can produce the extracellular matrix protein
chondroitin-sulfate proteoglycan (CSPG) that serves to inhibit axonal
regeneration following SCI (Bradbury, Moon et al. 2002). If E2 treatment can
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reduce astrogliosis, less CSPG will be deposited around the lesion and may
result in greater regeneration of axons and improved functional recovery. This
may be examined in a chronic model of SCI.
Glutamine synthase is another important marker of astrogliosis, and an
indirect measure of neuronal glutamate signaling and excitotoxicity (Benton,
Ross et al. 2000). This enzyme was significantly decreased with E2 treatment,
as shown by both Western blot and representative immunofluorescent image
(Figure 15). E2 treatment has been reported to upregulate glutamine synthase
expression in the hippocampus of non-injured mice (Blutstein, Devidze et al.
2006). These findings suggest glia may be responsive to endocrine signaling
control in neurotransmission, however, regulation in pathological states such as
those we are investigating in SCI have not yet been reported. More than one
potential mechanism may exist to explain these findings as E2 has also been
reported to decrease glutamate induced excitotoxicity through interaction with the
L-type voltage gated calcium channel in an in vitro model (Sribnick, Del Re et al.
2009). Given this, E2 may be decreasing glutamine synthase by initially acting to
decrease glutamate release from nearby neurons. Alternatively, as glial cells are
known to express E2 receptors (Santagati, Melcangi et al. 1994) , the effect on
glutamine synthase may be receptor mediated.
In addition to astrocytes, microglia, also contribute to reactive gliosis in
SCI. Activated microglia are characterized by the cellular marker Iba-1, a
calcium binding protein discussed previously (Ito, Imai et al. 1998), and by ED-1
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(CD68), a classic macrophage marker. Immunostaining revealed increased Iba1 and ED-1 staining in injury animals and decreased staining in E2 treated
animals (Figure 20 & 21). ED-1 is a marker that will label both infiltrating
monocytes expressing CD68 as macrophages as well as tissue resident
macrophages such as microglia. MCP-1, as discussed above, is a chemokine
that is released from damaged tissue to signal the infiltration of monocytes from
the periphery. At 6hrs post injury E2 treatment significantly reduced MCP-1
levels in both CSF (Figure 8) and plasma (Figure 10). In the present study, E2
treatment significantly reduced ED-1 positive staining, suggesting that the early
reduction of chemokines has resulted in less monocyte infiltration / macrophage
activation.
Activated microglia may further contribute to local inflammation by
release of factors such as COX-2 and iNOS. E2 treatment significantly
decreased COX-2 expression in whole spinal cord lysates (Figure 16), and
Western blot analysis (Data not shown) also revealed a non-significant decrease
in iNOS expression. COX-2 has been shown to be expressed in rat microglial
cells following nerve injury (Durrenberger, Facer et al. 2004). COX-2 expression
has also been shown in neurons and epithelial cells (Schwab, Brechtel et al.
2000, Lau, Wong et al. 2014). Given multiple cell types may contribute to COX-2
levels in the injured spinal cord, the exact contribution of microglia derived COX2 is yet unknown.
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In summary, nanoparticle delivered E2 revealed a distinct plasma
concentration profile from IV or IP dose routes. Nanoparticle dosing resulted in
delayed Tmax and decreased Cmax with prolonged elevated plasma
concentrations. This profile may prove to be more efficacious as it allows for E2
to exert neuroprotective effects for longer time. Additionally, as high Tmax is
avoided, nanoparticle delivery may provide a safer dosing strategy if applied
clinically.
Using an intermediate time model of 48 hrs the effects of E2 on the glial
cell response can be examined. E2 exerted multiple effects on glial cells,
including upregulation of GDNF, downregulation of the proinflammatory protein
COX-2, decreased reactive gliosis (glutamine synthase, GFAP, S100β), and
decreased microglia/macrophage activation (Iba-1 and ED-1). Taken together,
these findings suggest that at the protein level E2 may be exerting
neuroprotective effects through modification of the glial response. Reduction of
the glial response in the intermediate time period maybe critical to lessening glial
scarring in the chronic phase. Decreased astrogliosis has been shown to result
in decreased CSPG (inhibitor of axonal regeneration) production and glial
scarring (Li, Li et al. 2014). As numerous cell types express CSPG,
oligodendrocyte precursor cells, macrophages, and other invading immune cells
(McTigue, Tripathi et al. 2006) an approach that globally decreases astrogliosis
as well as infiltrating immune cells is warranted. The data presented here,
support the hypothesis that E2 may decrease glial scarring through modulating
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infiltrating immune cells and glial response at the intermediate time phase.

The

question remains, however, if nanoparticle delivered E2 as a single low dose
may drive improved locomotor functional recovery. These findings support the
evaluation of this novel E2 dosing approach in a functional model of SCI.
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CHAPTER FOUR

E2 NANOPARTICLES IN A FUNCTIONAL RECOVERY MODEL
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Introduction
In Chapters two and three E2 treatment was shown to exert a
number of biological effects in a peracute and intermediate model of SCI.
The peracute model illustrated the potential for E2 to act as a rapid antiinflammatory through modulation of cytokines in both systemic circulation
as well as in spinal cord tissue. The intermediate model revealed the
potential for E2 to exert extended biological effects after only a single
administration through decreased astrogliosis as well as additional protein
changes that suggest potential for enhanced recovery. While these early
findings are promising, the goal of enhanced functional recovery remains.
Hence, the focus of this specific aim will be evaluation of E2 nanoparticles
in a functional recovery model.
To examine motor function, two techniques will be used - the
Basso, Beattie, and Breshnahan (BBB) rating scale for locomotion, and
the DigiGait platform that utilizes ventral plane videography paired with
digitized image analysis. The BBB scale is a 21 point scale that scores
locomotor function of rats in an open field and has become a standard
endpoint in SCI models for nearly two decades (Basso, Beattie et al.
1995). The DigiGait platform is a relatively new technique whereby a
video camera mounted below a transparent walking belt captures high
resolution video of a rodent walking. Gait signals are generated through
the measurement of paw area on the belt over time.
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A step cycle is

comprised of two phases, the stride and stance phase. These phases are
further broken down into swing phase (time in which paw area is not in
contact with the belt), propulsion phase (paw area decreasing over time)
and braking phase (paw area increasing over time). These gait signals
are analyzed for 27 different metrics of gait such as gait symmetry, hind
paw area, swing to stance ratio, and hind paw rotation which have been
reported in the rat SCI literature (Springer, Rao et al. 2010, Zhang, Bailey
et al. 2015).
Functional recovery may also be assessed by neurogenic bladder
recovery. Normal bladder voiding requires the coordination of relaxation
of the external uretheral sphincter and contraction of the bladder detrusor
under control of spinal circuitry (de Groat 1998). Following injury to the
thoracic region of the spinal cord, the degree of impairment of bladder
voiding is correlated with white matter loss in regions involving urinationrelated tracks (Pikov and Wrathall 2001). A study has shown that a
positive correlation exists between severity of injury and functional deficits
of the bladder in rats (Ozsoy, Ozsoy et al. 2012). Reduction of GFAP
expression has been shown to improve neurogenic bladder recovery, as
measured through spontaneous voiding restoration (Toyooka, Nawashiro
et al. 2011). Given these findings, we hypothesize that E2 treatment may
result in earlier recovery of spontaneous bladder voiding.

107

Pathological changes to the spinal cord will also be assessed
through histological approaches. The formation of the wound cavity
following SCI is one of the primary barriers to regeneration. This cavity is
surrounded by fibrotic scar tissue, comprised of glial and fibrotic
components such as fibronectin and CSPGs, and serves to prevent
regeneration of axons across the lesion. Decreasing wound cavity size
and preservation of surrounding white matter tracts would serve to lessen
neurological impairment. To investigate how E2 treatment may modulate
wound cavitation and white matter sparing, Luxol fast blue (LFB) stain for
myelin will be conducted. Spinal cords will be collected and sectioned in a
sagittal orientation, which will allow for a qualitative assessment of the
wound cavity size as well as visualization of white matter sparing.

MATERIALS AND METHODS
Nanoparticles and Gel Plug Delivery System: Techniques will be the same as
described in Chapter 2 with the addition of a 5.0 µg dose group.
Rat SCI Model & Bladder Function: Induction of injury and treatment with E2
nanoparticle will be conducted as described for the 6hr & 48 hr models, with the
exception being time point for sacrifice will be extended to 28 days. Body weight
will be taken weekly. Bladders will be manually expelled 2-4 times daily. The day
in which an animal regains spontaneous voiding upon the first morning inspection
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of the animals will be recorded. For sham group, n=5, Inj + Veh n=10, Inj + 2.5 µg
E2 n=8, Inj + 5.0 µg E2 n=10.
Tissue Collection and Analysis: On Day 28 rats were deeply anesthetized under
ketamine / xylazine IP injection and euthanized via decapitation.

Spinal cord

samples were dissected, and a 1.5 cm piece was collected and divided into 0.5 cm
caudal, 0.5 cm lesion epicenter, 0.5 cm rostral to lesion. The tissue was placed
into cassettes and then into 4% neutral buffered formalin for 72 hours at room
temperature. Tissue was removed, paraffin embedded, and sectioned at 5 µM
thickness. Slides were then processed for routine H&E staining. In brief, slides
were (1). deparaffinized (2). Rehydrated (3). Hematoxylin staining 5 min (4). 1%
Acid Alcohol 1 dip (5). 1% Ammonia Alcohol 10 dips (6). Eosin staining for 10 sec
(7). EtOH (8). Xylene and coverslipped.

Luxol fast blue (LFB) staining was

conducted for detection of myelin. In brief, slides were (1). Deparaffinized (2). LFB
stained at 60⁰C for 2 hrs (3). EtOh (4). 0.05% lithium carbonate for 20 sec (5).
Differentiated in 70% EtOH and then followed up with H&E staining.
Assessment of Locomotor Function: BBB Animals were assessed for locomotor
function using the BBB scale beginning 24 hours after surgical induction and then
once weekly for 4 weeks as previously described (Basso, Beattie et al. 1995).
Scoring was performed by an experienced laboratory technician who was blinded
to treatment group. Statistical differences were determined by a Student’s T-test
for each week.
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DigiGait Analysis: On Day 28 animals were recorded on the DigiGait treadmill
system. Briefly, animals were placed on the belt and allowed to acclimate for 2
minutes at a low speed, 5 cm/sec. The speed was then increased to 20 cm/sec
and 1000 frames were captured, representing approximately 6 full step cycles.
Videos were analyzed on the DigiGait Analysis software package (Mouse
Specifics, Quincy MA) for 27 different indices of gait function.

In Vivo: Plasma and Spinal Cord Collection 48 hr profile study
A plasma and spinal cord profile study was conducted using the 5.0 µg E2 dose.
Whole blood drawn via tail vein puncture was collected into EDTA containing
tubes (final concentration EDTA 1.5 mg/mL).

Samples were collected at 1, 2, 4,

8, 12, 24, and 48 hrs following drug administration. Animals were serially bled,
n=3 per group, such that each animal underwent 6 tail vein bleeds and one final
cardiac stick. Whole blood samples were spun at 10,000 RPM in a Sorvall
Legend Micro21 bench top centrifuge, and plasma was collected and stored at 80°C. 17-β estradiol (E2) concentration was determined using a commercially
available ELISA kit (Calbiotech Estradiol ELISA ES180S), and kit directions were
followed exactly.
Cytokine Profiling: Plasma samples were collected at 24 and 48 hours from all
animals on the 28 day study. Samples were stored at -80°C and then shipped on
dry ice to Eve Technologies. Samples were run undiluted on the rat
cytokine/chemokine 27-plex discovery assay.
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RESULTS
Body Weight: Body weight measurements revealed similar changes between all
injury groups. Animals lose between 5-10% body weight in the first week
following surgery and then slowly regained the weight, ending the study with
approximately a 20% weight gain from their starting weight.
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Figure 22. Body Weight 28 the Chronic Model Body weight changes in
chronic 28 day SCI model. No significant changes in body weight between the
injury groups. n=4 sham, n=8 Inj + 2.5 µg E2, n=10 Inj + Veh and Inj + 5.0 µg E2
groups
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Bladder Function Recovery:
Bladder function recovery is defined here as the ability to spontaneously void the
bladder. The day in which this behavior is restored indicates the animal no
longer needs to be manually expressed. Both the Injury + Veh and Inj + 2.5 ug
E2 groups took an average of 9.7 ± 0.6 days to spontaneously void bladders.
The Injury + 5.0 ug E2 group took an average of 8 ± 0.5 days to spontaneously
void bladders.
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Figure 23. Bladder Function Recovery in the Chronic Model. Inj + Veh and
Inj + 2.5 ug E2 groups took 9.7 days to recover spontaneous bladder voiding,
while Inj + 6.0 ug E2 group took 8 days. * p<0.05 Inj + 5.0 ug E2 vs. Inj + Veh
group
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BBB Locomotor Recovery Assessment: BBB scoring revealed no difference
between the Inj + Veh group and the Inj + 2.5 µg E2. There is significant
improvement in BBB score on Day 7 between the Inj + Veh group and the Inj +
5.0 µg E2. There is a trend towards improved BBB score for days 14, 21, and
28.
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Figure 24. BBB Assessment in the Chronic Model. Significant improvement
in BBB score is found in the Inj + 5.0 ug E2 group, as compared with Inj + Veh on
Day 7. Sham animals, by criteria, are all scored a 21 at each time point and are
therefore not displayed.

* p<0.05 Inj + Veh vs. Inj + 5.0 ug E2. n=4 sham, n=8

Inj + 2.5 µg E2, n=10 Inj + Veh and Inj + 5.0 µg E2 groups

116

DigiGait Analysis: Stride Phase The stride phase of gait consists of
three phases: propulsion, brake, and swing. Sham animals, representing
normal gait, display a stride that is comprised of: 63% propulsion, 15%
brake, and 23% swing phases. The Inj + Veh group had a stride phase
comprised of 50% propulsion, 39% brake, and 11% swing phases. The
brake phase or time in which the hindlimb is in contact with the belt is
nearly three times as long in the injuried animals as in shams. This
illustrates the inability of the animal to properly initiate movement rather
the animal’s hind limbs remain in contact on the belt without movement.
The swing phase or phase in which hindlimb is not in contact with the belt,
is 50% reduced in the injuried animals. Inj + 5.0 ug E2 animals showed a
more normalized stride phase comprised of 50% propulsion, 30% brake,
and 20% swing phases. E2 treated animals have a significant reduction in
both brake and swing phases as compared with Inj + Veh groups,
representing a more normalized gait.
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Figure 25. DigiGait Stride Analysis in the Chronic Model. DigiGait stride
phase analysis shows the effect of SCI in the vehicle group with decreased
propulsion and swing phases and increased brake phase as compared with
sham controls. E2 treatment resulted in a significant decrease in both the brake
and swing phases. * p<0.05 Vehicle vs. E2 5.0 µg E2 groups. n=4 sham, n=10
Inj + Veh and Inj + 5.0 µg E2 groups
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DigiGait Analysis: Stance Phase The stance phase of gait is divided into
two phases, the brake and the propulsion phase. Sham animals display a
stance phase that is 81% propulsion and 19% brake. The propulsion phase
is defined as decreasing paw area contact on the belt over time, such as
the motion of a foot rocking from heel to lift off at the toe. Injury + vehicle
animals display a stance phase that is 56% propulsion and 44% brake. This
reduction in propulsion phase and increase in brake phase is reflective of
their hind limb paralysis. E2 treatment significantly decreased the brake
phase and trended towards increasing the propulsion phase (38% brake
and 62% propulsion phase).
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Figure 26. DigiGait Stance Analysis in the Chronic Model. DigiGait stance
phase analysis shows the effect of SCI in the vehicle group with decreased
propulsion and increased brake phase, as compared with sham controls. E2
treatment resulted in a significant decrease in the brake phase. * p<0.05 Vehicle
vs. E2 5.0 µg E2 groups. n=4 sham, n=10 Inj + Veh and Inj + 5.0 µg E2 groups
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DigiGait Analysis: Hind-limb shared stance, gait symmetry, and stride frequency
Additional parameters of gait were found to be significantly affected by E2
treatment. Hind-limb shared stance time is defined as the time that both hind
paws are in contact with the belt. This measure may indicate balance, as an
increased shared stance time is seen in unstable animals. Inj + Veh animals
have an increased shared stance time, and E2 treatment significantly decreased
shared stance time indicating a more stable posture. Gait symmetry is measured
by forelimb step frequency to hindlimb step frequency ratio. In spinal cord injured
animals, the loss of hindimb function results in a higher ratio, indicting more steps
are being taken by the forelimbs. Treatment with E2 resulted in a significant
decrease is the gait symmetry index, illustrating improved hindlimb function.
Finally, stride frequency is number of strides taken per paw per second. Sham
animals display a stide frequency of 1.5 ± 0.9 steps/s, Inj + Veh animals have a
reduced stride frequency of 1.02 ± 0.08 steps/s. E2 treatment significantly
increased stride frequency to 1.25 ± 0.05 steps/s.
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Figure 27. Additional DigiGait Analyses in the Chronic Model.

DigiGait

Parameters Affected by E2 Treatment. E2 treatment showed a significant
change in hindlimb shared stance time, gait symmetry, and stride frequency as
compared with vehicle treated animals.

* p<0.05 E2 5.0 µg E2 vs. Vehicle. n=4

sham, n=10 Inj + Veh and Inj + 5.0 µg E2 groups
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Histology: H&E and LFB Staining of Sagittal Spinal Cords Sagittal sectioning of
spinal cords paired with H&E staining allows for visualization of entire lesion
volume. Qualitatively, lesion volumes are reduced in the 5.0 µg dose group as
compared with the vehicle group. LFB staining allows for visualization of white
matter (blue) and gray matter (pink). Qualitative analysis reveals significant
white matter sparing, particularly along the ascending/descending columns in the
lateral portions of the spinal cord. Additionally, it can be seen that tissue integrity
is enhanced in the E2 treated group
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Vehicle

5.0 µg E2

Figure 28. H&E Staining of Sagittal Spinal Cords. Images taken at 20X
magnification. H&E staining reveal gross differences in lesion volume and tissue
architecture between Vehicle and E2 treated groups. n=4 per group
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Vehicle

5.0 µg

Figure 29. LFB Staining of Sagittal Spinal Cords. Images taken at 20X
magnification. LFB staining reveal differences in white matter (stained blue)
preservation between Vehicle and E2 treated groups. n=4 per group
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E2 Plasma Concentration Profiling: 5.0 µg vs. 2.5 µg E2 Given the 2.5 µg dose
was found to be ineffective for improvement of locomotor function, the dose was
increased to 5.0 µg. A plasma profile study reveals the differences in exposures
seen between the two groups. The Tmax for both groups was found to be 2
hours. The Cmax for the 2.5 µg dose was 172 pg/mL, and the Cmax for the 5.0
µg dose was 269 pg/mL. Besides this difference the plasma concentration
curves appear to be very similar.
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Figure 30. 5.0 µg E2 Plasma Concentration Time Course Experiment. Cmax
for the 5.0 µg group was found to be 269 ± 18 pg/mL, and 172 ± 27 pg/mL for the
2.5 µg group. n=3 per group
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Cytokine Analysis 24 & 48 Hr: At 24 hrs only one analyte, VEGF, was found to
be statistically different. VEGF was 39% increased in the 5.0 µg E2 group as
compared to a 4% decrease as seen in the vehicle group (25 pg/mL 5.0 µg E2,17
pg/mL vehicle group, 18 pg/mL Sham) (Figure 30). Other than VEGF no major
differences between groups were seen in the plasma cytokine profiles examined.
In general, all of the injured groups tended to have decreased
cytokine/chemokine levels when compared to the sham group (Figure 31). At 48
hrs following injury, no statistically different chemokines/cytokines profiles were
found between the E2 treated groups and vehicle. Although, it is interesting to
note that overall the 5.0 µg E2 group trended to have increased
cytokine/chemokine expression across the board (Figure 32).
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Figure 31. VEGF plasma levels at 24 hrs. Inj + 5.0 ug E2 group VEGF level
(25 pg/mL ± 1.4) was significantly increased as compared with Inj + Veh (17
pg/mL ± 1.2) *p<0.05 Inj + 5.0 µg E2 vs. Inj + Veh. n=3 per group
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Figure 32. Plasma Cytokine/Chemokine Profile 24 hrs. Plasma taken from
animals on 28 day study. Using the sham group as a control, the percentage
change from sham group was calculated for 13 different plasma analytes at 24
hrs post injury/E2 treatment revealed a trend for all injured groups to display
decreased cytokine/chemokine levels as compared to sham. n=10 vehicle, n=8
2.5 ug E2, n=10 5.0 ug E2.
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Cytokine Profile 48hr
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Figure 33. Plasma Cytokine/Chemokine Profile 48 hrs. Plasma taken from
animals on 28 day study. Using the sham group as a control, the percentage
change from sham group was calculated for 13 different plasma analytes. A
global increase in cytokines/chemikines and the growth factor VEGF were seen
at the 48hr time point in the 5.0 µg dose group. n=10 vehicle, n=8 2.5 ug E2,
n=10 5.0 ug E2
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Spinal Cord Tissue E2 Concentration 48 Hr: To continue to profile the release of
E2 from nanoparticles, spinal cord tissue was analyzed for E2 content at the end
of the plasma profiling study. The concentration of E2 was found to be 5.3 ± 0.7
pg/ug. Using the 6 hr tissue concentration study, the sham and vehicle groups
were found to be under 2 pg/ug, representing the lowest detectible concentration
on the ELISA format.
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Figure 34. E2 Tissue Concentration 48 hrs. E2 concentration in lesioned
spinal cord tissue determined via ELISA format. In the Inj + 5.0 µg group
concentration at 48 hrs was found to be 5.3 ± 0.7 pg/ug. This value is
approaching the normal range of E2 as seen in the sham and Inj + Veh group
taken from the 6 hr study. n=3 all groups
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DISCUSSION
The sub-acute and intermediate models provided data to support the
hypothesis that the 2.5 µg dose of E2, delivered in nanoparticle embedded gel
plugs, may be adequate to drive a functional improvement in the chronic model.
However, we found that the 2.5 µg dose of E2 was sub-efficacious for driving a
functional improvement. This finding is in agreement with the literature; to date,
there have been no reports of locomotor function recovery below 50 µg. The
lowest reported dose of E2, that has been shown to be efficacious for
improvement of locomotor function is reported to be an approximate dose of 25
µg (100 µg/kg) given IV 15 min following injury and again 24 hrs following injury
for a total dose of 50 µg (Hu, Sun et al. 2012). However, a single 50 µg
subcutaneous pellet dosage was not found to be efficacious (Kachadroka, Hall et
al. 2010). Our lab has found the lowest efficacious dose of E2, delivered for 7
days via osmotic pump, to be 10 µg/kg (data pending publication). Osmotic
pumps deliver E2 at a constant rate that results in steady state levels, similar to
pellet delivery. The differences between these studies may lie in the different
dosing techniques, resulting in different plasma exposures. However, as neither
paper reported E2 plasma levels, this cannot be determined.
Here, we report that the lowest efficacious dose of E2 was found to be 5.0
µg. This dose was found to decrease neurogenic bladder recovery time,
increase BBB scores, improve various DigiGait parameters of gait, and
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qualitatively spare white matter and decrease lesion volume in spinal cords.
Differences in plasma E2 concentration profiles between the 2.5 µg and 5.0 µg
dose groups reveal the only differences to be in the first two hours with a 50%
increased Cmax (Figure 27), suggesting that there may be a minimal Cmax
required to drive neuroprotection with E2. A formal pharmacokinetic study would
be required to support this hypothesis, however. Tissue concentration at 48 hrs
revealed only a modest increase in E2 concentration (approximately 5 times) as
compared with non-treated, 5.3 pg/µg vs.0.9 pg/µg vehicle (Figure 31). This was
an unexpected finding, as the 6 hr data revealed a tissue concentration of 162
pg/µg (Figure 6). E2 displays high affinity binding to the estrogen receptor β,
with a dissociation constant of 0.6 nM (Kuiper, et al. 1997). Given its properties
as a high affinity binder, even at low concentrations E2 may still be exerting
biological effects. Again, a formal pharmacokinetic study would be required to
test this hypothesis. Data presented here provide support for this hypothesis, as
the single 5.0 µg dose of E2 revealed improvements in both locomotor function
and spinal cord morphology. The single 5.0 µg dose is the lowest known
efficacious dose, and these findings potentially highlight the advantage of using
nanoparticle embedded gel plugs to focally deliver E2 and potential for clinical
translation in SCI.
Functional recovery following SCI was monitored by both locomotor
function as well as bladder function. Neurogenic bladder dysfunction has been
found to be correlated with spinal cord injury severity (Ozsoy, Ozsoy et al. 2012).
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Recovery of bladder function may therefore serve as a surrogate marker of injury
severity. Here we report that the 5.0 µg dose significantly decreased the number
of days required to reinstate bladder function (Figure 22). The recovery of
bladder occurs between days 6-12, illustrating that the effects seen by E2 at the
6hr and 48hr time points translates into improved spinal reflex control in the
chronic recovery period. Locomotor function was also improved, as seen in the
BBB scores and DigiGait analyses (Figures 23-25). These findings are found in
conjunction with histological analyses that qualitatively illustrate decreased lesion
volume and increased white matter sparing (Figures 27 & 28). The differences
seen in the lesion between vehicle and E2 treated groups may provide evidence
to support hypothesis that E2 is exerting neuroprotective effects by decreasing
secondary injury spread. Mechanisms contributing to secondary injury spread
such as inflammation, apoptosis, and reactive gliosis are mitigated by E2
treatment, as shown in Chapter 3. The lesions seen in the E2 group are fairly
compact with well-preserved tissue and well-defined borders, whereas the
lesions in the vehicle groups are spreading and diffuse (Figures 27 & 28). These
gross differences in lesion morphology highlight the potential for E2, when
applied in the acute time period following injury, to spare white matter tracts and
decrease secondary injury spread.
To further elucidate the neuroprotective mechanisms E2 exerts in SCI,
plasma was profiled at the 24 and 48 hr timepoints for 27 different analytes
(same profile as specific aim 1). Surprisingly, only one finding was statistically
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significant. VEGF was significantly increased at 24 hrs in animals treated with
5.0 µg E2. This particular finding was not surprising, however, as E2 receptors
have been reported to regulate VEGF gene transcription (Mueller, Vigne et al.
2000). Additionally, E2 receptors have also been shown to be involved in
activation of one of the VEGF pathways (VEGF/Akt/NO) leading to enhanced
angiogenesis through the VEGF receptor Kdr (Jesmin, Mowa et al. 2010).
Therefore, increased VEGF circulating in the plasma, triggered by E2, may be
beneficial by promoting angiogenesis in the lesioned spinal cord. The molecular
mechanisms underlying VEGF stimulation of angiogenesis have been well
studied and reviewed elsewhere (Evans 2015).
The panel of cytokines/chemokines at 24 hrs reveals that while the
majority of the analytes are reduced when compared to sham levels, the two
markers GRO-KC (human IL-8) and MCP-1 are elevated. This is consistent with
the findings in Specific Aim 1 where these two markers were found to be specific
to SCI and have been reported in the literature to be candidate biomarkers for
human SCI severity (Kwon, Stammers et al. 2010). At 48 hrs the most striking
trend is an overall increase in analytes in the 5.0 µg E2 dose group, although
none of these trends were found to be statistically significant. The overall lack of
robust cytokine regulation at 24 and 48 hrs post injury in both dose groups is
found in parallel with a loss of plasma exposure (Figure 29). Plasma E2 levels
nearly return to sham concentrations (15 pg/mL) by 48 hrs for the 2.5 µg E2 dose
group (21 pg/mL. The 5.0 µg E2 group had slightly elevated plasma E2 levels at
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48 hrs (37 pg/mL).

Perhaps, the global increase in cytokine/chemokines in the

5.0 µg E2 dose group is a rebound response as a result of decreased plasma E2
exposure. Further studies are warranted to better understand if E2 is playing an
active role in cytokine/chemokine response at this time point. Additionally, it
should be noted that the cytokine/chemokine response in the spinal cord tissue
was not investigated. Therefore, whether the plasma response is reflective of
lesioned spinal cord tissue is not known at this time point.
These data provide evidence that when delivered focally, a single low
dose of E2 may drive neuroprotection and improve locomotor recovery in a rat
model. To date, this is the lowest reported efficacious dose of E2, and by
monitoring plasma levels we have shown that by using the nanoparticle
embedded gel delivery technique plasma levels remain in a physiologically
relevant range. This novel approach may allow for a safe and efficacious drug
treatment option for use in acute SCI individuals.

138

139

CHAPTER 5
CONCLUSION AND FUTURE DIRECTIONS
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INTERPRETING THE RESULTS

E2 has been found to be a neuroprotectant in SCI by more than 10
groups to date (Elkabes and Nicot 2014). Given this plethora of data
supporting the use of E2, the question of clinical translation remains. This
dissertation examined a novel drug delivery technique, one that may allow
for clinical application of this promising therapeutic. In addition to
examining the hypothesis that a focal nanoparticle drug delivery may be a
clinically viable approach, mechanistic investigations were also conducted
to further uncover how E2 drives neuroprotection. In order to
systematically address mechanistic questions, three models were used to
examine signaling at peracute, intermediate, and chronic stages of SCI. In
this concluding chapter, an attempt will be made to analyze the findings
from each of these models in a broader sense and discuss clinical
implications.
Studies using a peracute (6hrs following injury) model have shown
here that E2 exerts a significant widespread anti-inflammatory effect. E2
was found to significantly decrease 15 analytes in the plasma
compartment. As Chapter 2 has already discussed specific cytokines,
this Chapter will place focus on a broader scale. These data provide
evidence that E2 can rapidly regulate the innate immune response. E2
receptors α and β are expressed in cells comprising the innate immune
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system (B cells, natural killer cells, monocytes) (Kovats 2015). These
cells are responsible for the production and release of the proinflammatory
cytokines into the plasma. Therefore, the hypothesis that E2 in circulation
may be rapidly regulating numerous cell types of the innate immune
system to downregulate cytokine production, thereby decreasing systemic
inflammation is reasonable. For clinical translation these data also
suggest the importance of using E2 very acutely following injury.
Moreover, E2 also exerted anti-inflammatory effects in the
damaged spinal cord tissue. These changes were mirrored in CSF;
however the mechanisms by which E2 may be exerting rapid antiinflammatory effects are driven by different cell types in tissue.
Spinal cord tissue consists of numerous cell types, including neurons,
astrocytes, oligodendrocytes, and microglia. All of these cell types
express E2 receptors, and all of these cell types have been reported to
express cytokines to varying degrees. The widespread expression of E2
receptors makes distilling the protective effects down to a single or even
few mechanistic pathways difficult. This complexity further highlights the
true pleiotropic nature of E2 in an injury setting.
The peracute model was designed to allow for profiling of 3 biological
compartments simultaneously. By doing so, we can gain tremendous insight into
how the plasma or CSF reflect the tissue. The data generated illustrated that 26
of the 27 markers in plasma could not differentiate between sham and injured
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animals. The one exception found was leptin. This is not altogether surprising
as the laminectomy procedure itself is an invasive surgical approach. CSF,
however, could differentiate between the sham and injured animals. The profile
of cytokines/chemokines in the CSF most closely mirrored those seen in the
lesioned tissue. These findings highlight the necessity of biomarkers to be
sampled from CSF in the clinical setting. Currently, clinical trials rely on
endpoints of functional recovery to determine efficacy, which require months to
years to acquire. The addition of biomarkers, that could be sampled in the acute
period following SCI from the CSF allowing for rapid identification of therapeutics
capable of decreasing key cytokines/chemokines may greatly progress the field.
The lack of dose response in the peracute model between 25 and 2.5 µg
doses also points towards a ceiling effect for E2. Essentially, the maximal
reduction that E2 may achieve is seen at 2.5 µg dose of E2. Interestingly, as the
2.5 µg dose did not result in improved locomotor recovery, the important factor
may be length of time during which E2 levels are high enough to drive maximal
cytokine/chemokine reduction. These findings imply that longer, lower level
plasma exposure to E2 may be most beneficial.
The intermediate model provided data to support the hypothesis that E2
may drive neuroprotection by decreasing astrogliosis. The bulk of previous
literature reports have focused on the effects of E2 on neuronal survival. Hence,
we focused on the glial cell response to E2 to potentially uncover novel
therapeutic mechanisms. Decreased astrogliosis at the 48hr time point may be
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linked to decreased cytokine/chemokine signaling at the 6 hr time point.
Cytokines and chemokines serve as molecular triggers for activation of systemic
and tissue immune cells, such as microglia and astrocytes. E2 treatment
reduced 15 different cytokines/chemokines in plasma and 11 in tissue at the 6 hr
time point. This translated into significantly decreased tissue astrogliosis at the
48 hr time point, further highlighting the importance of early treatment with an
inhibitor capable of pan cytokine/chemokine modulation.
Finally, in the chronic model, a minimal dose to drive improvement in
locomotor function was established. By using a focal nanoparticle drug delivery
approach, we report the lowest efficacious dose known to date. Additionally, by
reporting E2 levels in the plasma, a bench mark for future studies has been set.
Data presented herein suggest that a high Cmax is not required. This data is
vital for translation into clinical practice in regards to efficacy as well as safety.
Retrospective observational studies have indicated that an increased risk for
stroke occurs in women taking oral contraception (associated with high Cmax
and rapid clearance) vs. transdermal (associated with low steady state levels)
(Speroff 2010). These findings make it ill-considered to use a dosing technique
that results in a high E2 Cmax in SCI individuals, who are already at greater risk
for DVT. Rather, use a focal and sustained drug delivery technique, such as
nanoparticles may be more appropriate.

144

FUTURE DIRECTIONS
Data from the intermediate model revealed that by 48 hrs both tissue and
plasma concentration of E2 were near baseline levels. This finding was
somewhat unexpected as in vitro data suggested E2 was released for 6 days.
Regardless, the data reveal a need for a longer release nanoparticle formulation.
The current work utilized one population of nanoparticles, composed of a set
ratio of PLGA to PEG-PLA copolymer (10:2). By varying this ratio it is possible to
change the properties of the nanoparticles, such as size and charge, thereby
allowing for a different degradation rate. In future studies using a mixed
population of nanoparticles, one for rapid release and another for slower release
may be beneficial.
Continued work on acute biomarkers may better clarify the lack of efficacy
seen in chronic model at 2.5 µg E2 vs. the efficacy with 5.0 µg E2. More
specifically, how long do cytokines / chemokines need to be decreased? For
these studies, time course models examining plasma, tissue, and CSF will be
necessary. These data will provide profiles of cytokine/chemokine responses in
both an efficacious and non-efficacious dose that can be applied clinically and
may help determine clinical doses. For example, if the rat model illustrated that
MCP-1 must be 80% reduced for a minimum of 48 hrs, then in the clinical
situation CSF may be monitored and drug dosages adjusted accordingly.
The question remains of whether E2 may exert neuroprotection when
dosed in the chronic time period. Given there is a large population of individuals
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living with paralysis secondary to SCI, a need exists for treatment to potentially
enhance motor function in the chronic stage. SCI individuals currently undergo
extensive physical therapy, therefore, pairing exercise with E2 treatment in a
chronic model may be clinically relevant. The hypothesis that E2 paired with
forced exercise may improve locomotor recovery in a chronic model could be
evaluated using a chronic model and a treadmill training system. To further
study this hypothesis use E2 in conjunction with the scar dissolution drug
Decorin, may result in further enhanced recovery.
Finally, nanoparticle drug delivery approach may allow for a number of
drugs to be administered simultaneously. Pairing a cocktail approach with a
rationally timed delivery system, i.e. nanoparticles designed for slow delivery
loaded with drugs targeted to affect later occurring pathologies, may yield further
improved outcomes. Using drugs that are off-patent and have already been
investigated in SCI would offer the fastest approach for clinical application. One
such combination of drugs that could be tested in a cocktail nanoparticle delivery
approach could be E2 and Minocycline in quick release nanoparticles and Taxol
(microtubule stabilizing agent for enhanced axonal regeneration) in slow release
nanoparticles. Given the highly complex nature of SCI, it follows that a rational
combination drug therapy approach may prove the most effective in finding
successful treatment for this debilitating condition.
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